Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 1 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
  
UW19041 Therapeutic Combination of CLR 131 with 
External Beam Radiation in Head and Neck Cancer  
 
Principal Investigator s: Justine Yang Bruce, MD  
         Paul M. Harari, MD 
IND#: [ZIP_CODE] , Division of Oncology Projects 1  
IND Sponsor:  Cellectar Biosciences, Inc.  
 
  
[STUDY_ID_REMOVED]  
 
  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 2 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 2  
STATEMENT OF COMPLIANCE  
The study will be conducted in accordance with the International Council for  Harmonisation 
guidelines for Good Clinical Practice (ICH E6), the Code of Federal Regulations on the Protection 
of Human Subjects (45 CFR Part 46). All personnel involved in the conduct of this study have 
completed human subjects protection training.
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 3 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 3 SIGNATURE [CONTACT_357381], including all statements regarding confidentiality, and according to local legal and regulatory requirements and applicable US federal regul ations and ICH guidelines.  
Principal Investigator s: 
Signed:   Date:   
 Justine Yang Bruce, MD  
 Principal Investigator  
[INVESTIGATOR_357310]                                                                                  04Oct  [ADDRESS_445731] INFORMATION  ................................................................................. 16 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ........................ [ADDRESS_445732]/CT Dosimetry Evaluation .......................................................................................... 40 
6.7.1  Tumor and Organs at Risk (OAR) Dosimetry  ............................................................. 40 
6.8 External beam radiation therapy (EBRT)  ............................................................................... 40 
6.8.1  Dose specifications and target definition  .................................................................... 40 
6.8.2  Plan evaluation .......................................................................................................... 41 
6.8.3  Technical factors  ........................................................................................................ 41 
6.8.4  Definition of organs at risk and recommended dose constraints  .................................  41 
6.8.5  Prioritization for IMRT planning .................................................................................. 42 
6.9 Concomitant Medications/Treatments  .................................................................................... [ADDRESS_445733] CLR  131 Infusion ( ± 2 weeks)  .......................................................... [ADDRESS_445734] EBRT ( ± 4 weeks)  .............................................................................. [ADDRESS_445735] EBRT ( ± 4 weeks)  .............................................................................. [ADDRESS_445736] EBRT ( ± 6 weeks)  ............................................................................ [ADDRESS_445737] EBRT ( ± 6 weeks)/End of Study Visit  ................................................ 48 
7.4 Withdrawal Visit (+ 30 days)  .................................................................................................. 48 
7.5 Unscheduled Visit  .................................................................................................................. 48 
8 STUDY PROCEDURES /EVALUATIONS  ......................................................................................... 50 
8.1 Study Procedures/Evaluations  ............................................................................................... [ADDRESS_445738]/CT Imaging .................................................................................................... [ADDRESS_445739]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 6 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 6 8.1.13  Electrocardiogram (EKG)  ........................................................................................... 52 
8.1.14  Quality of Life Measures  ............................................................................................  52 
8.1.15  Oral Swab and Saliva Collection and Analysis  ........................................................... 53 
8.1.16  Oral profile exam (research procedure)  ...................................................................... 54 
8.1.17  Modified Barium Swallow Study  ................................................................................. 55 
8.1.18  Diagnostic Imaging .................................................................................................... 55 
8.2 Laboratory Procedures/Evaluations  ....................................................................................... [ADDRESS_445740] Radiation Precautions  ............................................................................................... 59 
11 ASSESSMENT OF SAFETY ............................................................................................................. 61 
11.1  Specification of Safety Parameters  ........................................................................................ 61 
11.1.1  Unanticipated Problems  ............................................................................................. 62 
11.1.2  Adverse Events  .......................................................................................................... 62 
11.1.3  Serious Adverse Events (SAE)  .................................................................................. 62 
11.2  Time Period and Frequency for Event Assessment and Follow -Up........................................ 62 
11.2.1  Adverse Events  .......................................................................................................... 63 
11.2.2  Serious Adverse Events  ............................................................................................. 63 
11.2.3  Other Reportable Events  ............................................................................................  63 
11.3  Characteristics of an Adverse Event  ...................................................................................... 65 
11.3.1  Relationship to Study Intervention  .............................................................................. 65 
11.3.2  Expectedness  ............................................................................................................ 65 
11.3.3  Severity of Event  ........................................................................................................ 65 
11.4  Reporting Procedures  ............................................................................................................ 65 
11.4.1  Unanticipated Problem (UP) Reporting to IRB, Cellectar and UWCCC DSMC ........... [ADDRESS_445741]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 7 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 7 14.3.2  Analysis of Secondary Endpoints  ............................................................................... 75 
15 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 77 
16 QUALITY CONTROL AND QUALITY ASSURANCE  ......................................................................... 78 
16.1  Monitoring, Auditing, and Data Quality Control and Assurance Measures  ............................. 78 
17 ETHICS/PROTECTION OF HUMAN SUBJECTS  ............................................................................. [ADDRESS_445742] ..................................................................................................... 79 
17.3  Informed Consent Process  .................................................................................................... 79 
17.4  Exclusion of Women, Minorities, and Children (Special Populations)  ..................................... [ADDRESS_445743] KEEPI[INVESTIGATOR_1645]  .................................................................................... 81 
18.1  Data Management Responsibilities ........................................................................................ 81 
18.2  Data Capture Methods  ........................................................................................................... 81 
18.3  Types of Data  ........................................................................................................................ 81 
18.4  Schedule and Content of Reports  .......................................................................................... 81 
18.5  Study Records Retention  ....................................................................................................... 82 
18.6  Protocol Deviations  ................................................................................................................ 82 
19 PUBLICATION/DATA SHARING POLICY  ......................................................................................... 83 
20 LITERATURE REFERENCES ........................................................................................................... 84 
APPENDICES  ........................................................................................................................................... 90 
APPENDIX A: SCHEDULE OF EVENTS ................................................................................................... 91 
APPENDIX B: ECOG EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS ...... 94 
SUPPLEMENTAL MATERIALS ................................................................................................................. 95 
 
TABLE OF TABLES  
Table 1:  Other Reportable Events Timeframe  .................................................................................. 64 
Table 2:  FDA Reporting Requirements.  ............................................................................................  67 
Table 3:  Dose escalation rules  .......................................................................................................... [ADDRESS_445744] OF ABBREVIATIONS  
 
3D Three dimensional  
AE Adverse Event/Adverse Experience  
ALT Alanine aminotransferase  
ANC  Absolute neutrophil count  
AST Aspartate aminotransferase  
BUN  Blood Urea Nitrogen  
BSA Body surface area  
CBC  Complete blood count  
CFR Code of Federal Regulations  
CLIA  Clinical Laboratory Improvement Amendments  
CLR 124  18-(p-[124I]-iodophenyl) octadecyl phosphocholine  
CLR 131 18-(p-[131I]-iodophenyl) octadecyl phosphocholine  
CLR1404  18-(p-iodophenyl)octadecyl phosphocholine  
CITI Collaborative IRB Training Initiative  
CoC Certificate of Confidentiality  
COPD  Chronic obstructive pulmonary disease  
CRC  Clinical Regulatory Committee  
CRF Case Report Form  
CT Computed tomography  
CTCAE  (NCI) Common Terminology Criteria for Adverse Events  
CVA Cerebrovascular event  
DHHS  Department of Health and Human Services  
DIGEST  Dynamic Imaging Grade of Swallowing Toxicity  
DLT Dose Limiting Toxicities  
DOT  Disease Oriented Team  
DSM C Data and Safety Monitoring Committee  
DSMS  Data and Safety Monitoring System  
EAT-[ADDRESS_445745]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 9 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 9 EKG  Electrocardiogram  
EORTC  European Organisation  for Research and Treatment of Cancer  
FDA Food and Drug Administration  
FLC Free Light Chain  
FFR Federal Financial Report  
FOIS  Functional Oral Intake Scale  
GCP  Good Clinical Practice  
GSL Glottic/supraglottic larynx  
Gy Gray  
HNC  head and neck cancer  
HNSCC  head and neck squamous cell carcinoma  
HIV Human immunodeficiency virus  
ICF Informed Consent Form  
ICH International Council for  Harmonisation  
IDE Investigational Device Exemption  
IMRT  intensity modulated radiotherapy  
IND Investigational New Drug Application  
IRB Institutional Review Board  
IUD Intrauterine device  
IV Intravenous  
KeV kiloelectron volts  
LINAC  linear accelerated -based  
mCi millicurie  
MDADI  MD Anderson Dysphagia Inventory  
MEP  Maximum expi[INVESTIGATOR_27111](s)  
MM Multiple myeloma  
MRI magnetic resonance imaging  
MTD  Maximum tolerated dose  
mTPI -2 modified toxicity probability interval  
N Number (typi[INVESTIGATOR_19737])  
OAR  Organ s at risk 
OHRP  Office for Human Research Protections  
ORR  Overall response rate  
OS Overall survival  
Cellectar                                                                                  04Oct  [ADDRESS_445746]  Response evaluation criteria in solid tumors  
rGTV  Recurrent gross tumor volume  
RMS  Residual Mucosal Saliva  
rPTV Recurrent planning tumor volume  
SAE Serious Adverse Event/Serious Adverse Experience  
SCC  Squamous cell carcinoma  
SF-[ADDRESS_445747]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 12 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 12 PROTOCOL SUMMARY  
Title:  Therapeutic Combination of CLR 131 with External Beam Radiation in Head and 
Neck Cancer  
Précis: This is a Phase 1 study of the use of an investigational drug, CLR 131 , in 
combination with external beam radiation therapy (EBRT) in subject s with 
locoregional ly recurrent  head and neck cancer . The trial will enroll up to [ADDRESS_445748] s at the Maximum Tolerated Dose (MTD) who  are amenable to 
retreatment with radiation therapy. Subjects who also have distant  metastatic 
disease may be enrolled on this clinical trial, but subjects must have evaluable 
disease that will be clinically treated with radiation therapy , as per standard of 
care. All subject s will receive a dosimetry test dose of CLR  [ADDRESS_445749]/CT imaging evaluation. Subject s showing uptake will receive 
a cumulative tumor dose of 60- 70 Gy using personalized dose calculation (via 
Monte Carlo methods) of CLR 131 combined with external beam radiation.  
  
Objectives:  Primary:   
• To evaluate the safety and tolerability of CLR [ADDRESS_445750] s with recurrent cancers of the 
head and neck. Outcome measure:  Incidence of adverse events assessed 
using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 
 
 Secondary:   
• To perform dosimetric  evaluation of CLR 131 in subjects with recurrent 
cancers of the head and neck . Outcome measure: CLR [ADDRESS_445751]/CT imaging and 3D dosimetric evaluations.  
• To assess tumor response following treatment with CLR 131 in 
combination with external beam radiation therapy. Outcome measure:  
Overall response rate (ORR) defined as the proportion of subjects who experience either a partial response or complete response within [ADDRESS_445752] of care 
imaging (e.g. CT, MR , PET -MR). 
• To evaluate changes in swallowing function before and after treatment with CLR 131 in combination with external beam radiation therapy. 
Outcome measure:  Swallow function assessed by [CONTACT_357339] (DIGEST) scale . 
• To evaluate changes in quality of life before and after treatment with 
CLR [ADDRESS_445753]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 13 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 13 measure:  Quality of life assessed by [CONTACT_357340] (MDADI).  
• To evaluate salivary flow rate before and after treatment with CLR  131 in 
combination with external beam radiation therapy. Outcome measure:  
stimulated salivary flow.  
 
  
Population:  Up to twelve adult  males and females of all races and ethnic groups with 
locoregionally recurrent head and neck cancer who may also have distant 
metastatic disease will be enrolled  at the Maximum Tolerated Dose.  
Phase:  I 
Number of Sites:  1, University of Wisconsin Carbone Cancer Center   
Description of  Intervention:  Following informed consent, all subject s will receive a dosimetry test dose of 
[ADDRESS_445754]/CT imaging evaluation.  
Subject s who have uptake of the CLR [ADDRESS_445755] s showing uptake will receive a 
cumulative tumor dose of 60- 70 Gy using personalized dose calculation of 
CLR 131 (via Monte Carlo) combined with external beam radiation.   In this 
study, we are also studying a subset of up to [ADDRESS_445756] s: (a) dose escalation and (b) 
dose expansion . In the dose escalation phase , an mTPI -2 design, an 
extension of modified toxicity probability interval (mTPI -2), will be used to 
identify the maximum tolerated dose ( MTD ) using cohorts of [ADDRESS_445757] dose on day 1 followed by [CONTACT_357341] 8.  
Treatment with CLR 131 on the dose escalation cohort will begin at dose level 1 (15.6 mCi/m2). Subjects  at dose level 1 will receive a n intravenous infusion 
of CLR 131 at 15.6 mCi /m
2 on day 1 followed by a second dose on day 8.  
Subjects  at dose level 2 will receive a n intravenous infusion of CLR 131 at 
18.75 mCi/m2 on day [ADDRESS_445758]/CT imaging will be performed on days 2, 3, [ADDRESS_445759]/CT imaging scans, the Bednarz lab will utilize the 
Monte Carlo method to predict absorbed dose of CLR [ADDRESS_445760]  will undergo external beam radiation therapy  (EBRT) to 
complete the designated radiation dose outlined in the re- irradiation plan, as 
per standard of care. Prior to CLR [ADDRESS_445761] EBRT,  quality of life  
measures  and salivary characteristics will be assesse d.  We anticipate the 
total study (baseline, CLR 131 administration, EBRT and 3, 6, 12  and 24 
month follow up assessments) to take 27 months per participant.  
 
Study Duration:  [ADDRESS_445762] Participation Duration:  27 months  
Estimated Time to Complete Enrollment:  20 months  
Date Accrual Goal Met / Study Closed to Accrual  April 18, [ADDRESS_445763]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 15 of 95 
 _____________________________________________________________________________________________________________________________________________________________  
 
 ___________________________________________________________________________________________________________________________________________ 
 
 
 15 Schematic of Study Design:  
 
*Approximately [ADDRESS_445764] INFORMATION 
Principal 
Investigator s:   Justine Yang Bruce, MD  
University of Wisconsin Carbone Cancer Center  
WIMR Room [ADDRESS_445765]  
Madison, WI [ZIP_CODE]  
Phone: (608) 262- 4961  
[EMAIL_4586]  
 Paul M. Harari, MD  
Department of Human Oncology  
University of Wisconsin School of Medicine and Public Health  
[ADDRESS_445766]  
Madison, WI [ZIP_CODE]  Phone: (608) 263- 5009  
[EMAIL_4593]
 
  
Co-Investigators:  Steve Y. Cho , MD  
Department of Radiology  
University of Wisconsin Carbone Cancer Center  
[ADDRESS_445767]  
Madison, WI [ZIP_CODE]  
Phone: (608) 263- 8340  
[EMAIL_6881]  
 
Adam Burr , MD  
Department of Human Oncology  
University of Wisconsin School of Medicine and Public Health  
K4/B63, [ADDRESS_445768]  
Madison, WI [ZIP_CODE]  Phone: (608) 262- 4669  
[EMAIL_6882]  
 
Randall J. Kimple, MD, PhD  
Department of Human Oncology  
University of Wisconsin School of Medicine and Public Health  
WIMR Room [ADDRESS_445769]  
Madison, WI [ZIP_CODE]  
Phone: (608) [ADDRESS_445770]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 17 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 17 [EMAIL_4587]  
 
Greg K. Hartig, MD  
Department of Surgery  
Division of Otolaryngology -Head & Neck Surgery  
University of Wisconsin School of Medicine and Public Health  
[ADDRESS_445771], MC 7375  
Madison, WI [ZIP_CODE]  
Phone: (608) 265- 8207  
[EMAIL_4588]  
  
Timothy M. McCulloch, MD  
Department of Surgery  
Division of Otolaryngology -Head & Neck Surgery  
University of Wisconsin School of Medicine and Public Health  
[ADDRESS_445772], MC 7375  
Madison, WI [ZIP_CODE]  
Phone: (608) 263- 0192  
[EMAIL_4589]  
 
Aaron M. Wieland, MD  
Department of Surgery  
Division of Otolaryngology -Head & Neck Surgery  
University of Wisconsin School of Medicine and Public Health  
[ADDRESS_445773], MC 7375  
Madison, WI [ZIP_CODE]  
Phone: (608) 262- 2876  
[EMAIL_4591]  
  
Tiffany Glazer, MD  
Department of Surgery  
Division of Otolaryngology -Head & Neck Surgery  
University of Wisconsin School of Medicine and Public Health  
[ADDRESS_445774], MC 7375  
Madison, WI [ZIP_CODE]  
Phone: (608) 265 -8207  
[EMAIL_4590]  
 Bryan P. Bednarz, PhD  
Department of Medical Physics  
University of Wisconsin School of Medicine and Public Health  
[ADDRESS_445775], L5/176  
Madison, WI  [ZIP_CODE]  
Phone: (608) [ADDRESS_445776]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 18 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 18 [EMAIL_6883]  
 
 
Susan Thibeault, PhD , CCC- SLP 
Department of Surgery  
Division of Otolaryngology  
University of Wisconsin School of Medicine and Public Health  
[ADDRESS_445777], Room 5107  
Madison, WI  [ZIP_CODE]  
Phone: (608) 263- 6751  
[EMAIL_6884]  
 
Nicole Rogus -Pulia, PhD , CCC- SLP 
Department of Medicine; Division of Geriatrics and Gerontology  
Department of Surgery; Division of Otolaryngology  
University of Wisconsin School of Medicine and Public Health  
Madison GRECC (11G), Room D4240  
2500 Overlook Terrace  
Madison, WI [ZIP_CODE]  
(608) 256- 1901 ext [ZIP_CODE]  
[EMAIL_6885]  
 
Nadine P. Connor, PhD, CCC -SLP 
Department of Communication Sciences & Disorders  
University of Wisconsin College of Letters and Science  
[ADDRESS_445778] Madison, WI [ZIP_CODE]  
Phone: (608)262- 1044  
[EMAIL_6886]  
 
Institutions:  University of Wisconsin Carbone Cancer Center  
[ADDRESS_445779]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 19 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 19 Other Key 
Personnel : Biostatisticians:   
Menggang  Yu, PhD  
Department of Biostatistics and Medical Informatics  
University of Wisconsin School of Medicine and Public Health 207c WARF Office Building  
[ADDRESS_445780]  
Madison, WI 537 26 
Phone: (608) 261- 1988  
[EMAIL_4596]  Clinical Trials Program Manager : 
Diana Trask  
Department of Human Oncology  
University of Wisconsin School of Medicine and Public Health  
K4/[ADDRESS_445781]  
Madison, WI [ZIP_CODE]  Phone: (608) 263- [ADDRESS_445782]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 20 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 20 2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE   
2.1 Background Information 
2.1.1  Head and neck cancer  
In 2018, it is estimated that 64,690 new cases of oral cavity, pharyngeal, and laryngeal cancers 
will occur, which accounts for approximately 3.7 % of new cancer cases in the [LOCATION_002] 
(Siegel  et al. , 2018) . Head and neck cancer is a complex heterogeneous disease that arises from 
various sites including the oral cavity, pharynx, larynx, paranasal sinuses and salivary glands. Over 90 % of tumors that originate in the oropharyngolaryngeal axis are squamous cell carcinoma 
(SCC) . Treatment for head and neck cancer  patients includes surgery, radiation and 
chemotherapy in various combinations. Although the majority of patients can be cured from head and neck cancers, those patients with locally advanced and/or recurrent head and neck cancer have a 5 year overall survival rate of approximately 50- 60% (Pulte & Brenner, 2010) . Cure rates 
have improved only marginally over the last 30 years (Siegel  et al. , 2015) . 
2.1.2  Locoregional recurrence  
Approximately 50%  of patients with head and neck cancer (HNC) manifest recurrence following 
initial treatment, and the majority of these recurrences are loco- regional (mouth, throat, neck) 
(Cognetti  et al. , 2008; Forastiere et al. , 2001; Forastiere et al. , 2008; Peters  et al. , 2010; Pi[INVESTIGATOR_357311]., 2009; Vokes  et al. , 1993) . Although a proportion of these patients remain potentially curable 
with further local treatment approaches (surgery, radiation, chemoradiation), retreatment is technically challenging and accompanied by a significant risk of irreversible damage to normal tissues.  
 
Surgery is often limited by [CONTACT_357342] (base of skull, neurovascular bundles), whereas radiation is often limited by [CONTACT_357343] (spi[INVESTIGATOR_1831], bone, cartilage). Although retreatment of head and neck cancer (via surgical re- resection or re- irradiation 
of previously treated sites) is warranted in the attempt to provide disease control, these 
aggressive modalities can result in profound adverse effects on patient health- related quality of life 
(QOL) (A. M. Chen  et al. , 2011; Dawson  et al. , 2001; De Crevoisier  et al. , 1998; Hehr  et al. , 2005; 
Hoebers  et al. , 2011; Kasperts  et al. , 2005; Kramer  et al. , 2005; Langer  et al. , 2007; Mendenhall  
et al. , 2008; Nag et al. , 1998; Salama et al. , 2006; S. A. Spencer  et al. , 2001; Stevens  et al. , 
1994) . There is a compelling need to identify improved treatment approaches for patients with 
locoregionally recurrent head and neck cancer.  
2.1.3  CLR 131 
CLR 131 [18-(p-[131I] -iodophenyl)octadecyl phosphocholine] is an investigational, radio- iodinated 
cancer therapy that exploits the tumor -targeting properties of phospholipid ethers (PLEs) and PLE 
analogs by [CONTACT_91617] (Mollinedo et al. , 2010; Weichert  et al. , 2014) . To produce CLR 131, 
the core PLE analog 18- (p-iodophenyl)octadecyl phosphocholine (referred to as CLR1404 or 
NM404) is radioiodinated with 
131I. 131I was chosen as the radioactive constituent due to its 8- day 
physical half -life and well -established therapeutic capabilities in multiple cancer types such as 
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 21 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 21 thyroid cancer, neuroblastoma, non- Hodgkin’s lymphoma, and hepatocellular carcinoma 
(Hackshaw  et al. , 2007; Macklis & Pohlman, 2006) .  
 
CLR 131 selectively delivers radiation to malignant tumor cells, thus minimizing radiation exposure 
to normal tissues; a scenario very difficult to achieve in HNC, even with the use of highly conformal radiation techniques. The mechanistic basis for the cancer -cell selective uptake 
involves interaction with lipid raft regions of the plasma membrane (Weichert  et al. , 2014)  In 
preclinical studies, CLR1404 radioiodinated with either 
124I for imaging purposes or 131I for 
radiotherapeutic purposes has been evaluated in both xenograft and spontaneous (transgenic) tumor models in mice and rats. Imaging studies with CLR 124 [18-( p-[
124I]-iodophenyl) octadecyl 
phosphocholine], which is chemically and structurally identical to CLR  131, have demonstrated 
cancer -cell selective uptake and retention in all but 3 of over 60 tumor cell models assessed. 
CLR 131 antitumor activity has been documented in various tumor cell models, including glioma, 
multiple myeloma (MM), breast, prostate, colorectal, ovarian, renal, pancreatic, uterine, and lung cancers (Weichert  et al. , 2014) . 
[IP_ADDRESS]  Tumor Selectivity  
The malignant cell selectivity of the alkyl -phospholipi[INVESTIGATOR_357312]. The term “lipid rafts” refers to specialized plasma membrane microdomains, rich in cholesterol and sphingomyelin that spatially organize signaling pathways regulating cell proliferation and survival (Gao  et al. , 2011; Lingwood & Simons, 2010) . 
 CLR 131 and a variety of structurally related molecules (Mollinedo, 2007; van Blitterswijk & 
Verheij, 2008)  use lipid rafts as portals of entry into the cell. There is greater abundance of lipid 
rafts in cancer cells as compared to normal cells (Li  et al. , 2006) , which is believed to be the 
mechanism for selective uptake of CLR  131. Following uptake, CLR1404 displays prolonged 
retention in organelle membranes. Retention of related compounds has been suggested to reflect decreased degradation by [CONTACT_357344] (Barratt  et al. , 2009) .  
 The selective accumulation and retention of CLR 131 within malignant cells shows strong promise 
in the imaging domain for tumor detection (Deming  et al. , 2014; Swanson et al. , 2015; Weichert  et 
al., 2014) . In addition, with slow degradation once inside the cell, thereby [CONTACT_357345], the therapeutic potential of CLR 131 becomes attractive (Morris  et al. , 2015; 
Weichert  et al. , 2014) . With β -emissions from 
131I having a median range of several millimeters , 
radiation from CLR 131 can be sharply deposited within local tumors.  
[IP_ADDRESS]  Preclinical studies using CLR  [ADDRESS_445783] been exceptionally 
promising. The experimental data confirms strong uptake and retention of CLR  131 in HNC 
xenografts, selective accumulation in tumor versus normal tissues, HNC xenograft growth inhibition with CLR 131, and more potent tumor growth inhibition when CLR  131 is combined with 
external beam radiation (Morris  et al. , 2015) . This promising combination will be tested in the 
current Phase [ADDRESS_445784]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 22 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 22  
[IP_ADDRESS]  Clinical Experience with CLR [ADDRESS_445785] received CLR 131.  
 
CLR 131 has been investigated in a Phase 1a dosimetry study in 8 subjects  with advanced solid 
tumors. This study demonstrated that a single 10 mCi infusion of CLR  131 was exceptionally well 
tolerated. Whole body dosimetric analyses demonstrated that a dose of 20 mCi was predicted to 
deliver 40 cGy to marrow, and this information guided initial dosing in the subsequent therapeutic 
study.  CLR 131 was then examined in a Phase 1b therapy trial in 10 subjects  with advanced solid 
tumors. Doses up to 25 mCi/m
2 were well tolerated without dose- limiting toxicity. Dose -limiting, but 
reversible, thrombocytopenia and leukopenia were observed at doses of 31.25 mCi/m2 and 
higher. Hematocrit, renal function, and liver function were not significantly affected at doses up to 37.5 mCi/m
2. This study documented selective tumor uptake quantified by [CONTACT_357346]- emission 
CT/CT  (SPECT/CT)  imaging. Stable disease was observed in [ADDRESS_445786] -infusion.  
 
CLR 131 in combination with dexamethasone is currently under investigation in a Phase 1 trial in 
subjects  with relapsed/refractory  multiple myeloma ( MM) following treatment with both a 
proteasome inhibitor and an immunomodulatory agent. All subjects  have been heavily pretreated. 
Seven  dose cohorts were examined: 12.5 mCi/m2, 18.75 mCi/m2, 25 mCi/m2, 31.25 mCi/m2, and a 
multiple dose cohort s of 15.6 25 mCi/m2, 18.75 mCi/m2 and 20 mCi/m2 administered twice , all in 
combination with 40 mg dexamethasone weekly.  Thirty -one patients were dosed and the 
independent Data Monitoring Committee confirmed seven dose levels safe and tolerated.  The 
overall response rate for patients receiving <60 mCi total body dose  was 7% (1/15) and 27% 
(3/11) for patients receiving a > [ADDRESS_445787] common treatment emergent adverse events were cytopenias, primarily thrombocytopenia, with very predictable onset, time to nadir and recovery. Beyond cytopenias, fatigue was also a frequently reported adverse event. .  
 CLR 131 is also under investigation in a Phase 2 study in relapsed or refractory B -Cell 
malignancies  (CLOVER -1) where [ADDRESS_445788] been enrolled to date . Patients received either 
< 60 or ≥ 60 mCi total body dose CLR 131 (25 mCi/m
2 single bolus, 31.25 mCi/m2 fractionated or 
37.5mCi/m2 fractionated) either as a bolus dose or fractionated with half on day 1 and half on day 
7 ± 1 day. Patients enrolled in the final dosing group in Part A (Group 4) received an alternate two cycle fractionated dose schedule: fractionated 30 mCi/m
2 CLR 131 as 15 mCi/m2 on Day 1, Day 
15 (±1 day) for the first cycle, and then repeated Day 57 (± 1 day), and Day 71 (± 1 day) for the 
second cycle (total body dose ≥ 60 mCi). The adverse event profile remains consistent with the 
Phase 1 trial, with the primary treatment emergent adverse events including cytopenias; most 
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 23 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 23 commonly thrombocytopenia. The time to onset, nadir, and recovery continue to be predictable 
and the events manageable. Fatigue has also been reported commonly.  
 CLR 131 is also under investigation in a Phase 1 study of solid tumor and malignant brain tumors in children, adolescents, and young adults. This is a dose escalation study with a starting dose of 15 mCi/m
2. To date, ten patients have been enrolled.  
 Additional information about these trials is available in the CLR 131 Investigator’s Brochure  
(Supplementary Materials) . 
2.2 Rationale  for a clinical study using CLR 131 in combination with EBRT  
Locoregional recurrence in HNC represents a significant challenge. Approximately 50 % of HNC 
patients will experience loco- regional disease recurrence following initial therapy that commonly 
includes primary or postoperative radiation. Although some recurrent HNC patients can experience long- term tumor control following re- irradiation, thi s approach must be considered with 
great caution due to the risk of severe injury to normal tissue structures that maintain long- term 
recall from the prior radiation expos ure.  
 Several studies have specifically examined the role of re- irradiation in HNC with general 
conclusions that there is considerable risk for high- grade toxicities (including death), but a defined 
opportunity for long- term survival (2 years) in approximately 10 -20% of patients (A. M. Chen  et al. , 
2011; Dawson et al. , 2001; De Crevoisier  et al. , 1998; Hehr  et al. , 2005; Hoebers  et al. , 2011; 
Kasperts  et al. , 2005; Kramer  et al. , 2005; Langer  et al. , 2007; Mendenhall  et al. , 2008; Nag et al. , 
1998; Salama et al. , 2006; S. Spencer  et al. , 2003; S. A. Spencer  et al. , 2001; Stevens  et al. , 
1994) . 
 Selection of patients who would most likely benefit from HNC re- irradiation remains an area of 
active investigation.  Efforts to reduce the acute and long- term tissue injury profile by [CONTACT_357347]. With the use of CLR 131, the dose of external beam radiation therapy can potentially be reduced or more 
precisely targeted, which serves to limit high dose radiation therapy to normal tissues in the head and neck.    The aim of this clinical trial is to evaluate the use of the novel radioisotope CLR 131 as a modality 
to provide “internal radiation” to recurrent disease in combination with EBRT . This combination 
regimen would be intended to provide definitive treatment of recurrent head and neck cancer by [CONTACT_357348] [ADDRESS_445789] of care (SOC) radiation dose 
Cellectar                                                                                  04Oct  [ADDRESS_445790] 
specific symptoms, such a s quality of life, salivary flow and swallowing function.   
 
2.3 Potential Risks and Benefits  
2.3.1  Potential Risks  
[IP_ADDRESS]  CLR [ADDRESS_445791] s with advanced solid malignancies, CLR 
131 was well tolerated; adverse events (AEs) included fatigue, constipation, and sialadenitis. During the Phase 1b dose escalation study, bone marrow suppression (including thrombocytopenia, anemia, decreased white blood cell [WBC] count, and neutropenia), fatigue, and an increase in gamma glutamyl transferase were observed. In the ongoing Phase [ADDRESS_445792] been decreases in platelet count, hemoglobin, lymphocyte count, neutrophil count, and white blood count; for subject s receiving single or multiple 
dose CLR 131. Of note, subjects receiving multiple dose CLR 131 required fewer transfusions (platelet and red blood cell) and growth factor support than subjects receiving a comparable single dose (both 25 mCi/m
2 and 31.25 mCi/m2) of CLR 131. [ClinicalTrials.gov [STUDY_ID_REMOVED]]   
 
Cellectar                                                                                  04Oct  [ADDRESS_445793] s should be monitored for signs and 
symptoms of bone marrow suppression, such as fever, fatigue, dyspnea, and bleeding.  
 Since CLR 131  is a radioactive drug , it is possible that  subjects could expose others (like family or 
caregivers) to radiation.  Specific instructions about how to minimize this risk will be provided to 
research participants.  
 Additional information about potential adverse events  is available in the CLR  131 Investigator’s 
Brochure (Supplementary Materials) . 
[IP_ADDRESS].1  Thyroid- protection medication  
Side effects of KI (potassium iodide) may include stomach or gastro -intestinal upset, allergic 
reactions, rashes, and inflammation of the salivary glands.  In rare instances, it can cause “Iodism” (metallic taste, burning mouth and throat, sore teeth and gu ms, symptoms of a head cold, and 
sometimes upset stomach and diarrhea) or an allergic reaction can have more serious symptoms. These include fever and joint pains; swelling of parts of the body (face, lips, tongue, throat, hands, or feet); trouble breathi ng, speaking, or swallowing; wheezing or shortness of breath. Severe 
shortness of breath requires immediate medical attention.  
[IP_ADDRESS].2  Dose Limiting Toxicities (DLT)  Probably Related to CLR 131 
In this study, expected toxicities include febr ile neutropenia, anemia, thrombocytopenia, and 
fatigue  including, in some instances, Grade 3 and Grade 4. Per the CLR 131 Investigator 
Brochure, 90%  of subject s are anticipated to have blood count recovery approximately 65 days 
after treatment with CLR  131. In this study, a DLT is defined as : 
 
• Grade 4 neutropenia > 4 weeks  
• Grade 4 anemia > 4 weeks  
• Grade 4 thrombocytopenia > 4 weeks  
 
 
• Grade 3 neutropenia > 8 weeks  
• Grade 3 anemia > 8 weeks  
• Grade 3 thrombocytopenia > 8 weeks  
  
• Any other Grade [ADDRESS_445794] s in cohort recover to non- DLT levels or meet 
the criteria above.  
[IP_ADDRESS]  External beam radiation therapy  (EBRT)  
Radiation side- effects in the treatment of head and neck cancer are well known.  Though subjects 
for this trial will be given EBRT as part of standard of care, we are listing the side effects here to distinguish from those that are expected as part of CLR 131 administration.   
Common side effects include: mucositis, difficulty swallowing which may necessitate a feeding tube, dry mouth, change in taste and smell, reduced saliva production, hoarseness, radiation dermatitis, ear pain/infection, hearing loss, fatigue, weight loss, dehydration requiring IV fluids and electrolyte replacement, hair loss, tooth decay, decreased thyroid function. Rare and serious side effects include: breathing and swallowing issues that require a tracheotomy, nerve damage in the head and neck region, radiation necrosis of the jaw , damage to the larynx  or nerves, damage to 
the skin, soft tissues or other parts of the head and neck that may require a surgery to correct  and 
damag e to the spi[INVESTIGATOR_357313] . 
[IP_ADDRESS]  Modified Barium Swallow (MBS) Studies (standard of care)  
To minimize risk, the procedure has been carefully planned. Radiation dose received during a MBS (between 0.2 and 0.85mSv ) is lower than doses received from other common fluoroscopic 
and interventional radiology procedures. The risk of developi[INVESTIGATOR_007] a fatal cancer from a MBS is 1 in 39,000. Occasionally, patients may be allergic to the flavoring added to the barium.  There is a slight chance that barium could be retained in the gastrointestinal (GI) system, leading to a blockage. Women should inform their physician or x -ray technologist if there is any possibility that 
they are pregnant.  
[IP_ADDRESS]  Single photon- emission computed tomography ( SPECT ) /CT  
There is no additional risk associated with SPECT acquisition. However, a  low-dose spi[INVESTIGATOR_198214] ( CT) scan will accompany every SPECT acquisition for attenuation 
correction, anatomical conformation and dosimetry. The effective radiation dose associated with 
the low-dose spi[INVESTIGATOR_357314]; however, for the purposes of this study 
population we anticipate radiation exposure from CT scans to be ~1.5 m Sv/scan (maximum total 
radiation from 5 scans would be ~7. 5 mSv).  For comparison, estimates for natural background 
radiation in the [LOCATION_002] (vary based on location) is ~3. 1 mSv/year.  
[IP_ADDRESS]  Other risks  from study -related procedures  
• B lood draws  for clinical laboratory testing: bruising, swelling at the injection site, 
dizziness and lightheadedness   
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 27 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 27 • Saliva and oral swab collection:  dry mouth (expected to resolve within a few minutes 
following collection)  
• M aximum expi[INVESTIGATOR_27111] (MEP) and voluntary cough : subject may feel  slightly out 
of breath immediately following the measurement  (expected to resolve within a few 
minutes  of procedure) . 
• Maximum lingual pressure:  subject may experience discomfort or soreness of the 
tongue measurement  (expected to resolve within a few minutes  of procedure) .   
• Questionnaires:  risk of loss of confidentiality is possible but not likely with data security 
safeguards in place.  
 
2.3.[ADDRESS_445795] s’ participation in this study. While there is hope that a 
subject ’s cancer will respond to treatment with CLR 131, there is no proof of that at this stage. 
There is no standard treatment regimen for patients with locoregionally recurrent head and neck 
cancer, and thus re- irradiation with EBRT  can be considered for patients in order to provide long 
term disease control. However, patients who undergo re- irradiation for recurrent disease 
experience significant toxicities and side effects. Thus, patients with locally recurrent head and neck cancer  have an unmet need for treatment options with acceptable side effects and t oxicities. 
This study is likely to yield knowledge about the use of CLR [ADDRESS_445796]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 28 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 28 3 OBJECTIVES  
3.1 Study Objectives 
3.1.1  Primary Objective  
• To evaluate the safety  and tolerability  of CLR [ADDRESS_445797] s 
with recurrent cancers of the head and neck  
3.1.2  Secondary Objective s 
• To perform dosimetric evaluation of CLR 131 in subjects with recurrent cancers of the 
head and neck  
• To assess tumor response following treatment with CLR 131 in combination with external 
beam radiation therapy  
• To evaluate changes in swallowing function before and after treatment with CLR 131 in 
combination with external beam radiation therapy  
• To evaluate changes in quality of life before and after treatment with CLR 131 in 
combination with external beam radiation therapy  
• To evaluate salivary flow rate before and after treatment with CLR  131 in combination with 
external beam radiation therapy  
3.2 Study Outcome Measures  
3.2.1  Primary  
• Incidence of adverse events assessed using Common Terminology Criteria for Adverse 
Events (CTCAE) version 5.0  
3.2.2  Secondary  
• Median radiation treatment time and median number of dose delays due to toxicity  
• CLR [ADDRESS_445798]/CT imaging and Monte Carlo calculations  
• Overall response rate (ORR) defined as the proportion of subjects  who experience either a 
partial response or complete response within [ADDRESS_445799] of care imaging (e.g. CT, MR, PET-MR) 
• Swallow function assessed by [CONTACT_357349] ( DIGEST ) 
scale  
• Quality of life (QoL) assessed by [CONTACT_357350] ( MDADI ) 
• Salivary flow rate  related quality of life assessed by [CONTACT_357351]                                                                                  04Oct  [ADDRESS_445800] dose of CLR 131 (flat dose of 15 mCi) to establish drug 
uptake by [CONTACT_7879] .  
 Subject s who have tumor  uptake of the CLR  [ADDRESS_445801]/CT imaging by [CONTACT_357352].   Any subject  who demonstrates tumor uptake of CLR [ADDRESS_445802]/CT 
imaging after the test dose will continue to participate in the treatment portion of the study.  Up to 
six participan ts who do not demonstrate tumor uptake of CLR  [ADDRESS_445803]/CT will also continue 
with the treatment portion of the study.  Based on prior experience of subject s receiving CLR  131, 
75 % of eligible subject s are estimated to demonstrate CLR [ADDRESS_445804] s showing uptake will receive a cumulative tumor dose of 60- 70 Gy using personalized 
dose calculation of CLR  131 (via Monte Carlo) combined with external beam radiation. If the 
Monte Carlo dose estimate for any subject  is greater than 60 Gy for the 2 doses of CLR 131 
(highly unlikely based on preliminary data), then no additional external beam dose will be administered.  
 
All subjects will start thyroid -protection medication the day prior to the CLR [ADDRESS_445805] dose on day 1 followed by [CONTACT_357353] 8. The dose of CLR  131 will be based 
on the dose escalation schema. 
 
Dose Escalation Schema  
Dose Level  Dose s** of CLR 131 
-1* 12.5 mCi/m2 
1 15.6 mCi/m2 
2 18.75 mCi/m2 
*Dose level - [ADDRESS_445806] four patients will be given Dose 1. Dose - 1 will only be 
used if toxicities warrant de- escalation.  
** Dose level listed is administered first on day [ADDRESS_445807]/CT imaging will be performed on days 2, 3, [ADDRESS_445808]/CT imaging scans, the 
Bednarz lab will perform  the Monte Carlo calculations  to predict absorbed dose of CLR [ADDRESS_445809]  health- related measures: quality of life  and salivary flow rate . 
Swallow function will be assessed at baseline, [ADDRESS_445810] completion of EBRT ( standard 
of care Modified Barium Swallow ( MBS ) and research- related oral profile exam) see Schematic of 
Study Design).  
 Enrollment to the study is anticipated to take approximately [ADDRESS_445811] will 
participate for approximately 27 months , although only about four months will be active 
participation.  Details of the study schedule, including lab draws and specific study procedures are 
provided in section 7.  
 
Incomplete dosing of CLR 131 within study timeframe:  
In the event a participant is unable to receive the full study course of CLR [ADDRESS_445812] to continue with the CLR 131 administration, their scheduled appointments, labwork 
and SSKI  administration will be adjusted appropriately to accommodate the delay. If it is deemed 
in the participant ’s best interest to proceed to SOC EBRT , the following scenerios will occur:  
 
• Only test dose ( 15 mCi) CLR 131 administered:   
o Continue SSKI until [ADDRESS_445813] CLR 131 administration  
o P roceed with EBRT and SOC follow -up. 
 
• If test dose and a single therapeutic dose are administered :  
o C ontinue with SSKI until14 days post CLR 131  administration  
o U ndergo imaging for calculations of EBRT dose de- escalation  
o P roceed to EBRT  
 Modify EBRT dose based on the single therapeutic injection  
o C ontinue follow -up per protocol.  
 
Cellectar                                                                                  04Oct  [ADDRESS_445814] s treated at the MTD are planned for the study. The number of subjects in the 
expansion cohort will depend on the number of subjects treated in the mTPI -2 design (Section 
14.2). Adult men and women of all races and ethnic groups are eligible for this trial.  
 
5.[ADDRESS_445815] meet all of the following 
criteria:  
1. Subjec t must be informed of the investigational nature of the study and must be able to sign 
a written informed consent.  
2. Subject s with histologically or cytologically confirmed solid malignancy that has recurre d in 
the head and neck (above the clavicles)  region , e.g., subject s with recurrent cutaneous 
squamous cell carcinoma, salivary gland tumors or esthesioneuroblastoma are eligible for 
this clinical trial.  
3. Subject  is [ADDRESS_445816] one evaluable (measurable or non- measurable) recurrent 
lesion that is amenable to radiation therapy.  
7. Subject s must demonstrate uptake of CLR [ADDRESS_445817]/CT imaging, as determined by 
[CONTACT_357354], in the specified site of recurrent/metastatic disease that is to be treated with radiation therapy.   There is a subset of up to [ADDRESS_445818]/CT scan after the test dose.  
8. Subject s must have an ECOG performance status of 0 –  1. 
9. Subject s must have a life expectancy of at least [ADDRESS_445819]  has adequate hematologic function, as evidenced by:  
• an absolute neutrophil count (ANC) ≥ 1500 / µL 
• hemoglobin ≥9 g/dL (5.58 mmol/L)  
• and platelets ≥100,000  / µL 
o If full-dose anticoagulation therapy is used, platelets ≥ 150,000  / µL are required.  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 32 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 32 • If subject  is on full- dose anticoagulation therapy, the anticoagulation therapy 
must be reversible,  and reversal of the anticoagulation therapy must not be life-
threatening, as judged by [CONTACT_093].  
11. The subject  has adequate renal function as defined by:  
• serum creatinine ≤ 1.5 times the upper limit of normal ( ULN)  or Cockcroft -Gault 
calculated creatinine clearance ≥  60 ml/min  
12. The subject  has adequate hepatic function as defined by:  
• total bilirubin ≤ 1.5 mg/dL (25.65 μmol/L)  
• aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3.[ADDRESS_445820]  
13. Women of childbearing potential (WOCP) have a confirmed negative urine pregnancy test 
within [ADDRESS_445821] use a medically acceptable method of birth control such as an oral, 
implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device 
(IUD), a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal j ellies or cream), or total abstinence during the study participation and for [ADDRESS_445822] 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP.  
15. Men who are not surgically or medically sterile agree to use an acceptable method of contraception. Male subject s with female sexual partners who are pregnant, possibly 
pregnant, or who could become pregnant during the study must abstain from intercourse for three weeks after each CLR [ADDRESS_445823] dose of study drug. Total abstinence for the same study period is an 
acceptable alternative.  
 
5.3 Exclusion Criteria  
An individual  who meets any of the following criteria will be excluded from participation in this 
study:  
1. Recurrent tumor recommended for surgical resection based on multidisciplinary Head and Neck Oncology Tumor Board Review  
2. Thyroid cancer  
3. Known hypersensitivity to iodine  
4. Other concurrent severe and/or uncontrolled concomitant medical or psychiatric conditions (e.g. active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol, per investigator  discretion  
Cellectar                                                                                  04Oct  [ADDRESS_445824] dose of CLR  131 (alopecia and fatigue excluded). Clinical significance to 
be determined by [CONTACT_1697].  
7. The subject  is pregnant , breastfeeding, or expecting to conceive or father children within 
the projected duration of the trial, starting with the screening visit through [ADDRESS_445825] dose of trial treatment.  
8. Any ongoing or active infection, including active tuberculosis, hepatitis B or C, or known infection with the human immunodeficiency virus (HIV)  
9. Concurrent treatment with any other anti -cancer or investigational agents . Subject s cannot 
be receiving concomitant chemotherapy, radiotherapy, experimental therapy or any other therapy not otherwise outlined by [CONTACT_357355] -cancer treatment.  
10. Patient with a history of or concurrent second primary malignancy (stage III or IV) within  5 
years to study enrollment are excluded.   
11. Patients with a history of prior invasive malignancy (except early -stage I or II non-
melanomatous skin cancer, carcinoma in situ of the breast, cervical carcinoma in situ, stage I -II papi[INVESTIGATOR_6686], or low or very low -risk prostate cancer which has been 
completely treated with surgery or radiation) treated within [ADDRESS_445826] had prior systemic 
radioisotope therapy (except for benign thyroid disease)  
13. Poor venous access and will be unable to receive study drug into a peripheral venous catheter.  
14. Significant traumatic injury within [ADDRESS_445827]  
16. Any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to study entry  
17. History of myocardial infarction, ventricular arrhythmia, stable/unstable angina, symptomatic congestive heart failure, coronary/peripheral artery by[CONTACT_236934] 6 months prior to study entry  
18. QT interval corrected for heart rate using Fridericia’s formula (QTcF) ≥480 ms . 
19. Any condition requiring the use of immunosuppression, excluding rheumatologic conditions 
treated with stable doses of corticosteroids  (equivalent to  ≤ prednisone 10 mg dail y) 
20. Ongoing hemodialysis or peritoneal dialysis  
21. Poorly controlled severe COPD  
Cellectar                                                                                  04Oct  [ADDRESS_445828] s will be recruited from the treating physicians ’ own clinical practice, through clinic 
contacts, and referring physicians.  
 
5.4.[ADDRESS_445829] remuneration 
Subjects will be eligible to receive remuneration to offset the barriers of additional visits required to participate in this study. Subjects are eligible to receive $[ADDRESS_445830]/CT 
scan (s) needed following the test dose and an additional $[ADDRESS_445831]/CT scan following the first treatment dose of CLR  131. 
 
5.[ADDRESS_445832] s who agree to participate and who provide written informed consent will be enrolled via 
the University of Wisconsin Carbone Cancer Center (UWCCC) Oncore database by [CONTACT_357356] -specific participation. All subject s must meet eligibility 
criteria as listed above. The research staff will verify eligibility, assign a case number, and register the subject  in OnCore prior to study -specific participation. The following information will be 
recorded:  
• Protocol number  
• Subject ’s name 
• Subject ’s medical record number  
• Subject  demographic data  
The subject  will also be registered with Cellectar Biosciences to ensure drug product availability 
and shipment. Information to be provided to Cellectar Biosciences includes: assigned subject 
identification number, initials,  year of birth, body surface area, and dates of planned CLR [ADDRESS_445833] Withdrawal  
Treatment may continue as specified in the above treatment modality sections or until one of the 
following criteria applies:  
• disease progression;   
• intercurrent illness that prevents further administration of treatment;   
• unacceptable adverse event(s)  (as determined by [CONTACT_423] , treating physician)  
• subject  decides to withdraw consent for participation in the study;   
• subject  refuses further treatment (without withdrawing consent for study participation);   
• general or specific changes in the subject 's condition render the subject  unacceptable for 
further treatment in the judgment of the investigator;   
• new data related to the experimental agent which would suggest that continuing treatment 
on protocol would impose unwarranted potential risks beyond what was known at the time of treatment initiation.   
• a female subject becomes pregnant  
 
Subjects will be removed from protocol therapy and the site investigator notified when any of the criteria listed above apply. The reason for discontinuation of protocol therapy will be documented on the electronic case report form ( eCRF ). 
5.6.[ADDRESS_445834] decides to withdraw from the study (and not just from protocol therapy) all efforts should be made to complete and report study assessments as thoroughly as possible. The subject should be encouraged to complete the w ithdrawal visit  procedures outlined in Section [ADDRESS_445835]’s s tudy withdrawal should be made with an explanation of 
why the subject is withdrawing from the study. If the reason for removal of a subject from the study is an adverse event, it will be recorded on the eCRF.  
 
Cellectar                                                                                  04Oct  [ADDRESS_445836]  withdraws from the study prematurely, s(he) must continue taking the thyroid-
protection medication for [ADDRESS_445837] ( IRB) and will provide the reason(s) for the termination or 
suspension.  
Reasons for early study discontinuation may include , but are not limited to:  
• Unacceptable toxicity of study drug  
• Request to discontinue the study from a regulatory authority  
• Protocol violations  
• Poor enrollment  
• Company business decision 
• Difficulties in manufacturing the investigational product  
Cellectar                                                                                  04Oct  [ADDRESS_445838] Description 
 
 CLR 131 (also referred to as I -131-CLR1404 or [131I] -CLR1404) is supplied as a ready -for-use 
radiopharmaceutical for IV dosing. Two formulations of CLR 131 are used:  
• For CL1, CLR 131 is provided as a clear, faint yellow to yellow, sterile solution consisting of CLR 131 (18- (p-[
131I]-iodophenyl) octadecyl phosphocholine) and CLR 1404 (18- (p-
iodophenyl) octadecyl phosphocholine) in sodium chloride injection US Pharmacopeia (USP), ethanol USP, polysorbate 20 National Formulary, and sodium ascorbate USP.  
 
• For CL2, CLR 131 is provided as a clear, colorless to yellow, sterile solution consisting of CLR 131 (18- (p-[
131I]-iodophenyl) octadecyl phosphocholine) and CLR 1404 (18- (p-
iodophenyl) octadecyl phosphocholine) in sodium chloride injection US Pharmacopeia (USP), ethanol USP, polysorbate [ADDRESS_445839] be filtered 
through a 25 mm 0.2 micron sterile filter prior to administration.  
 CLR 131 is radioactive and should only be prepared, assayed, and administered by [CONTACT_357357]. Proper radiation shielding should be used during storage, preparation, assay, and administration of CLR  131. The study drug will arrive from 
Cellectar  Biosciences in a lead shippi[INVESTIGATOR_357315].  
CLR 131 Injection is shipped at room temperature (20 –  25 °C; 68 –  77 °F) with excursions during 
shippi[INVESTIGATOR_31081] - 40 – 70 °C ( -40 – 158 °F) allowed. When received at the site, the drug product is to be 
stored as per the lead shield label.  
• For CL1 formulation (identified in lot number as (N -xxxxxxCL1 -x), the drug product is to be 
stored refrigerated (2 – 8 °C; 36 –  46 °F). If CLR 131 is refrigerated ≤ 72 hours after 
radiolabeling the shelf -life is 14 days; if the drug product is refrigerated > 72 hours after 
radiolabeling the shelf -life is 11 days.  
• For CL2 formulation (identified in lot number as (N -xxxxxxCL2 -x), the drug product is to be 
stored upright at 15 – 25 °C, as directed on the label.  
 
The physical (radioactive) half -life of I -131 is 8.02 days. I -131 decays with beta emissions of 334 
keV (7  %) and 606 keV (90 %) and subsequent gamma emissions of 284 keV (6 %), 364 keV (82  
%), and 637 keV (7 %).  
 
See the CLR  131 Radiopharmacy Manual (Supplementary Materials ) for specific handling, 
preparation, administration, and storage requirements.  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 38 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 38 6.1.1  Acquisition  
CLR 131 will be provided by [CONTACT_357358]’ designated manufacturer and delivered 
directly to the institution in a just -in-time manner.  
6.1.2  Formulation, Packaging, and Labeling  
CLR 131 Injection:  
• Is packaged in single use glass vial(s);  
• Must be filtered through a 25 mm  0.2 micron sterile luer -lock syringe filter (or equivalent) 
prior to administration;  
• Must be diluted with 0.9 % Sodium Chloride for Injection, USP and thoroughly mixed prior 
to administration via slow IV infusion;  
6.1.[ADDRESS_445840] Storage and Stability  
CLR 131 Injection:  
• Should not be subjected to temperatures below - 20 degrees centigrade  
(-4 degrees Fahrenheit);  
• Should be stored as per the lead shield label and infused at room temperature; and  
 
• When product is prepared in an appropriate sterile environment as per the instructions in 
the CLR [ADDRESS_445841].  
 
Note: the CLR [ADDRESS_445842]  based on total 
body surface area ( BSA) (not to exceed 2.5 m
2) calculated from actual body weight  and height . 
The subject  will be clinically monitored for adverse reactions during the infusion and for [ADDRESS_445843] dose +[ADDRESS_445844] dose +[ADDRESS_445845] dose  
 
Potassium iodide tablets 130 mg orally once daily are the preferred thyroid protection medication. 
Acceptable alternatives, per institutional preference, include the following:  
• Saturated solution of potassium iodide (SSKI) 2 drops orally twice daily  
• Lugol’s 5 % solution 0.8 mL (approximately 16 drops) orally twice daily  
 
Subjects must receive two doses of SSKI, two doses of Lugol’s 5  % solution or one potassium 
iodide tablet (130 mg) prior to CLR [ADDRESS_445846] maintain a careful inventory of the study drug. Study drug use will be recorded on a study drug inventory form. At a minimum, this form will contain the following information:  
• Subject number and initials for each subject receiving study drug  
• Date, quantity and dose (mCi) of study drug received by [CONTACT_977] 
• Date, quantity and dose (mCi) of study drug dispensed  
• Date, quantity and dose (mCi) administered  
 Periodically, a Cellectar Biosciences’ representative will reconcile the information on the study drug inventory form with the actual inventory of study drug used at the clinical site. All used and expi[INVESTIGATOR_357316] 131 will be stored at the clinical site in long half -life radioactive 
storage per the clinical site’s standard operating procedures (SOPs) until background levels are reached (approximately 80 days). Once background levels are reached, the Cellectar Bioscienc es’ 
representative wil l return to do a final accountability check of the now -decayed vials. The clinical 
monitor will instruct the site on disposition of the vials either to ship to Cellectar Biosciences for disposal or discard per their SOP for waste disposal.  
Cellectar                                                                                  04Oct  [ADDRESS_445847] ’s proper use of thyroid  protection medication will be confirmed prior to 
every CLR 131 infusion and at appropriate follow- up visits.  
 
It is recommended that the Investigator or his/her designee contact [CONTACT_1130] s by [CONTACT_357359]- protection medication is started and a minimum 
of 2 doses of SSKI, 2 doses of Lugol’s 5  % solution, or 1 potassium iodide tablet (130 mg) are 
taken prior to CLR [ADDRESS_445848]/CT Dosimetry Evaluation  
6.7.1  Tumor and Organs at Risk (OAR) Dosimetry  
Subjects will obtain SPECT/CT images of the tumor and organs at risk at sequential imaging time points (days 2, 3, 4 -6, and 7- 8) after administration of the first treatment dose  of CLR 131.  
 SPECT/CT images of tumor and organs at risk will be reconstructed using quantitative SPECT reconstruction methods with compensation for attenuation, scatter and the full collimator -detector 
response including septal penetration and scatter. A registered CT  image will be used as the 
attenuation map for the SPECT images. Image data will be converted to activity per cubic centimeters using a sensitivity measurement made using a point source in air. For studies where the count rate is such that greater than 5% count rate losses are expected, deadtime corrections 
will be applied. The time activity curve in each pi[INVESTIGATOR_357317] a mono- or bi-
exponential function  when possible or a pi[INVESTIGATOR_13959]- wise linear fit when more advanced fitting options 
are not possible. The fits will be integrated and divided by [CONTACT_357360] a 3D 
residence time image. This will be converted to a dose image using the RAPID Monte Carlo dose estimation code (A. Besemer & Bednarz, 2014; A. E. Besemer  et al. , 2017; A. E. Besemer  et al. , 
2018) . The average dose and 3D dose distribution in each tumor and organs at risk will then be 
computed inside volumes -of-interest defined using CT and SPECT images.  
6.8 External beam radiation therapy (EBRT)  
External beam radi ation therapy will be used in combination with CLR  [ADDRESS_445849] of care.  The total dose (60- 70 Gy) 
delivered to the recurrent tumor will be at the discretion of the treating Radiation Oncologist.  
6.8.1  Dose specifications and target definition 
The recurrent gross tumor volume (rGTV), as defined by [CONTACT_357361] [ADDRESS_445850]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 41 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 41 will undergo a geometric expansion of 3 -5 mm to create the recurrent clinical target volume 
(rCTV), which accounts for coverage of areas at high- risk for harboring subclinical disease. The 
rCTV can be modified by [CONTACT_357362] (e.g. air space, bone). The rCTV will be expanded by 2- 3 mm to create a recurrent 
planning target volume (rPTV). Elective treatment volumes treated to lower dose are generally discouraged but permitted at the discr etion of the treating physician.  
6.8.2  Plan evaluation  
Plans will be normalized so that 95  % of the rPTV  is covered by [CONTACT_247374] (PD). The 
dose to 1cc of the rPTV should not exceed 115  % of the PD. The dose to 0.3 cc of the rPTV 
should not be less than 92  % of the PD.  
6.8.[ADDRESS_445851] scan simulation using ≤  [ADDRESS_445852]  has 
contra- indications (e.g. IV contrast allergy or poor kidney function). Treatment will be delivered via 
linear accelerated- based (LINAC) intensity modulated radiotherapy (IMRT) using high energy 
photon beams. Subject s will be treated with image- guidance radiotherapy. Images will be 
approved prior to the first treatment and following all remaining treatments by a staff Radiation 
Oncologist. Images will be registered either manually or automatically. The region- of-interest for 
image fusion should include the primary tumor and adjacent spi[INVESTIGATOR_1831]. Following registration, translation corrections should be applied to the treatment couch.  
6.8.4  Definition of organs at risk and recommended dose constraints  
Organs at risk (OARs) in subject s undergoing re- irradiation may have already approached or 
exceeded their respective recommended dose limitation. For example, during the initial treatment course, one or both parotid glands may have already exceeded the recommended dose of less than [ADDRESS_445853]: The spi[INVESTIGATOR_357318] -cervical junction (i.e. between the foramen 
magnum and the top of the C1 vertebral body). Superior to this is the brainstem and inferior is the spi[INVESTIGATOR_1831]. The inferior border of the spi[INVESTIGATOR_357319] T3- 4 (i.e. [ADDRESS_445854] slice containing rPTV). The spi[INVESTIGATOR_357320]. All attempts to limit the combined total dose from the previous and current radiation treatment regimen ( CLR 131 and EBRT) to less than [ADDRESS_445855] 
maximum point dose including prior radiation course will not exceed  65 Gy.  
  
Brainstem:  The inferior most portion of the brainstem is at the cranial -cervical junction between 
the foramen magnum and top of the C1 vertebral body. The brainstem will be contoured to the 
level of the posterior clinoid. The brainstem will be defined based on the t reatment planning CT 
scan. All attempts to limit the combined total dose from the previous and current radiation treatment regimen ( CLR 131 and EBRT) to less than 70 Gy will be made. Higher point doses can 
be considered and are at the discretion of the treating physician, however the brainstem maximum point dose including prior radiation course will not exceed  72 Gy.  
 Parotid glands:  Parotid glands will be defined based on the treatment planning CT scan. The 
contours will not include the accessory duct (i.e. gland anterior to the masseter muscle). The treatment planning goal for the parotid gland that received a lower previous radioth erapy dose 
should be a mean dose of < 26 Gy, but ideally as low as possible given data suggesting a no threshold dose response. Depending on the dose received by [CONTACT_357363] a higher mean dose from the previous treatment, a constraint shoul d be made by [CONTACT_1963].  
 Glottic/Supraglottic larynx (GSL):  This will be defined as a volume that begins just inferior to the 
hyoid bone and extends to the cricoid cartilage inferiorly and extends from the anterior commissure to include the arytenoids. This includes the infrahyoid and excludes the suprahyoid epi[INVESTIGATOR_175648]. The GSL mean dose from retreatment should be ≤ 3 5 Gy. 
 Mandible:  This includes the entire boney structure of the mandible from TMJ through the 
symphysis. The recommended maximum dose within the mandible should be <  35 Gy. This 
assumes a maximum dose approaching 60 Gy from the previous radiotherapy treatment plan. Therefore, a goal of < 105  Gy should be achievable with contribution from C LR 131. 
 Pharyngeal constrictors:  This includes the structure along the posterior pharyngeal wall from the 
inferior border of the pterygoid plates to the inferior border of the cricoid. A planning goal for a mean dose of < [ADDRESS_445856]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 43 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 43 6.9 Concomitant Medications/Treatments  
All intercurrent medical conditions will be treated at the discretion of the Investigator according to 
acceptable community standards of medical care. All concomitant medications and treatments will be documented appropriately  and recorded until [ADDRESS_445857] treatment dose  of CLR 131, which ever is later . 
 The following medications are not permitted during the study unless mandated by [CONTACT_357364]:  
• Any other investigational treatment  
• Any other systemic antineoplastic therapy including, but not limited to, cytotoxic chemotherapy, immunotherapy, monoclonal antibody therapy, systemic radioisotope 
therapy  
• Prophylactic hematopoietic growth factors (note: therapeutic hematopoietic growth factors are permitted at the discretion of the treating physician)  
Pneumocystis jiroveci p neumonia ( PJP) and viral prophylaxis for subjects with lymphopenia 
should be considered and is at the discretion of individual investigators.  
Initiation of platelet transfusions are suggested for subject s with a platelet count 
≤ 20,000  / μL or 
those subject s with symptomatic thrombocytopenia (evidence of bruising or bleeding).  
Cellectar Biosciences  advises investigators to refrain from initiating highly myelosuppressive 
therapy in subjects progressing within [ADDRESS_445858] 
satisfy the entry criteria.  Procedures and data collection at screening are:   
• Signed informed consent form (ICF)  
• Demographics (birth date, gender, race, ethnicity)  
• Medical history, including comprehensive treatment history for underlying malignancy  
• Review of concomitant medications  
• Physical examination  
• Vital signs  
• Height, weight  
• ECOG performance status  
• Complete blood count (CBC) with differential  (within [ADDRESS_445859] dose to determine 
eligibility)  
• Serum chemistries  (within [ADDRESS_445860] dose t o determine eligibility)  
• EKG (within [ADDRESS_445861] dose to determine eligibility)  
• Urine p regnancy test for WOCP (within [ADDRESS_445862] dose)  
• Serum thyroid- stimulating hormone (TSH) and free thyroxine (T4)  
• Dispense thyroid- protection medication and review instructions with subject s. 
Thyroid- protection medication must be taken within [ADDRESS_445863] CLR 131 dose.  
• Adverse event evaluation  
• Distribute medication diaries  
• Quality of Life surveys  
• Saliva and oral swab collection  
• Modified barium swallow study  
• Oral profile exam  
• Diagnostic cross- sectional imaging (any combination of CT , MR, or PET -MR) scans) 
collect ed from the scans performed as part of standard clinical care . 
• Dosimetry Test Dose  
• SPECT/CT imaging  
Cellectar                                                                                  04Oct  [ADDRESS_445864] Dose  
On the day of dosing, prior to infusion, the following tests and procedures will be done:  
• Confirm subject  is taking thyroid- protection medication as directed  
• Urine pregnancy test for WOCP (within [ADDRESS_445865] dose)  
• Vital signs will be collected prior to and [ADDRESS_445866] dose, t he dose of CLR  131 will be a flat 
dose of 15 mCi.  
• SPECT/CT imaging will be performed  approximately three days  after infusion to assess 
tumor uptake of CLR  131.  If a subject does not demonstrate CLR [ADDRESS_445867]/CT scan, then a repeat SPECT/CT  can be performed [ADDRESS_445868] 
dose to reassess for uptake.   
• Subjects who demonstrate uptake of CLR  [ADDRESS_445869]/CT 
scan , along with up to six patients who do not demonstrate uptake of  CLR [ADDRESS_445870] dose and treatment dose will be 7- 14 days , but will 
allow for to up to four weeks . Dosing dates for treatment can be scheduled to start - 1 or +3 days to 
accommodate clinic scheduling (e.g., holidays, weekends, treating physician schedules, etc.) . 
[IP_ADDRESS]  Treatment Dose Administration  
Subjects who have uptake on SPECT/CT imaging scans are eligible for the treatment portion of 
the clinical trial. These subjects will be treated and evaluated as follows:  
• Vital signs will be collected prior to and [ADDRESS_445871] CLR 131 infusion 
• On day [ADDRESS_445872]  based on total BSA (not to exceed 2.5 m
2) 
calculated from actual body weight  and height  at screening.  
• SPECT/CT imaging will be performed on days 2, 3, 4- 6, and 7 -8. 
• A second treatment dose  of CLR  131 will be given on day 8 . 
• CBC with differential and serum chemistries weekly for 12 weeks  (beginning at day [ADDRESS_445873] 
treatment dose) 
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 46 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 46 • Confirm subject is  taking thyroid protection medication as directed. 
• Adverse event evaluation  
• Urine pregnancy test for WOCP  (within 24 hrs prior  to each CLR 131 dose) 
[IP_ADDRESS]  External beam radiation therapy (EBRT)  (approximately 7- [ADDRESS_445874] CLR 131 
treatment dose)  
Based on the calculated absorbed dose of CLR  [ADDRESS_445875] CLR 131 Infusion ( ± 2 weeks)  
One month (± 2 weeks) after the first therapeutic CLR 131 dose, the following tests and 
procedures will be done:  
• Review of concomitant medications  
• Physical examination  
• Vital signs  
• Weight  
• ECOG PS  
• CBC with differential   
• Serum chemistries  
• Confirm subject is  taking thyroid- protection medication as directed  
• Adverse event  evaluation  
7.3.[ADDRESS_445876] EBRT ( ± 4 weeks)  
Three months (± 4 weeks) after EBRT is completed, the following tests and procedures will be 
done:  
• Review of concomitant medications  
• Physical examination  
• Vital signs  
• Weight  
• ECOG PS  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 47 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 47 • CBC with differential  
• Serum chemistries  
• TSH and free T4  
• Adverse event  evaluation  
• Oral profile exam  
• Modified barium swallow study  
• Quality of Life surveys  
• Saliva and oral swab collection  
• Diagnostic cross sectional imaging (any combination of CT, MR , or PET-MR scans) 
collected from the scans performed as part of standard clinical care  
7.3.[ADDRESS_445877] EBRT ( ± 4 weeks)  
Six months ( ± 4 weeks) after EBRT is completed, the following  tests and procedures will be done:  
• Review of concomitant medications  
• Physical examination  
• Vital signs  
• Weight  
• ECOG PS  
• TSH and free T4  
• Adverse event  evaluation  
• Oral profile exam  
• Modified barium swallow study  
• Quality of Life surveys  
• Saliva and oral swab collection  
7.3.[ADDRESS_445878] EBRT ( ± 6 weeks)  
Twelve months ( ± 6 weeks) after EBRT is completed, the following tests and procedures will be 
done:  
• Review of concomitant medications  
• Physical examination  
• Vital signs  
• Weight  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 48 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 48 • ECOG PS  
• TSH and free T4  
• Adverse event  evaluation  
• Quality of Life surveys  
• Saliva and oral swab collection  
• Diagnostic imaging (any combination of CT, MR, or PET -MR scans)  collect ed from the 
scans performed as part of standard clinical care   
7.3.[ADDRESS_445879] EBRT ( ± 6 weeks) /End of Study Visit  
(Note: this follow -up assessment will not be completed if the subject has initiated a new, anti -
cancer therapy prior to the 24 month visit.)  
Twenty -four months ( ± 6 weeks) after EBRT is completed, the following tests and procedures will 
be done:  
• Physical examination  
• TSH and free T4  
• Adverse event  evaluation  
• Diagnostic imaging (any combination of CT, MR, or PET -MR scans)  collect ed from the 
scans performed as part of standard clinical care  
7.4 Withdrawal Visit  (+ 30 days)  
If a subject withdraws or the investigator terminates subject participation prior to [ADDRESS_445880] 
EBRT , the following  tests and procedures will be done:  
• Review of concomitant medications  
• Physical examination  
• Vital signs  
• Weight  
• ECOG PS  
• Adverse event evaluation  
7.[ADDRESS_445881] an urgent or emergent medical condition will be seen by [CONTACT_177705]/or emergency room and treated as clinically indicated. Medical records will be obtained to evaluate for any adverse events, which will be documen ted in the clinical study 
database. In addition, the principal investigator, in conjunction with the treating physician, will 
Cellectar                                                                                  04Oct  [ADDRESS_445882]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 50 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 50 8 STUDY PROCEDURES /EVALUATIONS  
8.1 Study Procedures /Evaluations  
 
8.1.1  Demographics  
Birth date, gender, race, and ethnicity will be collected at screening  (recorded for the study from 
medical records maintained as part of standard clinical care) . 
8.1.[ADDRESS_445883] ’s medical history, taking into account all recent and pertinent 
medical conditions including prior cancer treatment, will be performed at screening (within [ADDRESS_445884] dose infusion) . This will be recorded for the study from 
medical records maintained as part of standard clinical care.  
8.1.[ADDRESS_445885] dose infusion of 
CLR 131(screening period) . A review of concomitant medications will occur at one month post the 
first CLR 131 therapeutic infusion; a t 3, 6, and [ADDRESS_445886] EBRT;  and at the withdrawal  visit. 
This will be recorded for the study from medical records maintained as part of standard clinical care for the screening  period as well as the  3, 6, and [ADDRESS_445887] CLR 131 therapeutic infusion visit and at the 
withdrawal  visit (if terminated early) . 
8.1.4  Physical Exam  
A detailed physical exam will be completed at screening ; at one month post the first CLR 131 
therapeutic infusion; at 3, 6, and [ADDRESS_445888] EBRT; and at the withdrawal  visit. This will be 
recorded for the study from medical records maintained as part of standard clinical care for the screening period as well as the 3, 6, and [ADDRESS_445889] CLR 131 therapeutic infusion visit and at the withdrawal  visit 
(if terminated early) .  
8.1.5  Vital Signs  
Vital signs (blood pressure, pulse, respi[INVESTIGATOR_697], and temperature) will be recorded prior to and [ADDRESS_445890] each CLR 131 infusion and at the following timepoints: screening ; one month post the 
first CLR 131 therapeutic infusion;  at 3, 6, and [ADDRESS_445891] EBRT; and at the withdrawal  visit. 
This will be recorded for the study from medical records maintained as part of standard clinical care for the screening period as well as the 3, 6, and [ADDRESS_445892] CLR 
131 therapeutic infusion visit and at the withdrawal  visit (if terminated early) . 
Cellectar                                                                                  04Oct  [ADDRESS_445893] procedure being done within routine care 
guidelines.  
8.1.7  Weight  
Weight will be recorded at screening; at one month post the first CLR  131 therapeutic infusion; at 
3, 6, and [ADDRESS_445894] EBRT; and at the withdrawal  visit (if applicable) . This will be recorded for 
the study from medical records maintained as part of standard clinical care for the screening 
period as well as the 3, 6, and [ADDRESS_445895] CLR 131 ther apeutic infusion visit and at the withdrawal  visit (if 
terminated early) . 
8.1.[ADDRESS_445896] ’s performance scale ( PS) based on the Eastern Cooperative 
Oncology Group (ECOG) rating scale (Appendix B ) will be made at screening; at one month post 
the first CLR 131 therapeutic infusion; at 3, 6, and [ADDRESS_445897] EBRT; and at the withdrawal  
visit (if applicable) . This will be recorded for the study from medical records maintained as part of 
standard clinical care for the screening period as well as the 3, 6, and [ADDRESS_445898] CLR 131 ther apeutic infusion 
visit and at the withdrawal visit (if terminated early) . 
8.1.[ADDRESS_445899]’s proper use of thyroid -protection medication will be confirmed at Day 1, 
prior to every CLR 131 infusion, and at applicable follow -up visits to ensure the appropriate use. 
Refer to Section 6.3 for dosing and duration details.  
It is recommended that the Investigator or his/her designee contact [CONTACT_1130] s by [CONTACT_357359]- protection medication is started and a minimum 
of 2 doses of SSKI, 2 doses of Lugol’s 5  % solution, or 1 potassium iodide tablet (130 mg) are 
taken prior to CLR [ADDRESS_445900] clinical procedure being done 
for research- related purposes associated with the administration of the research drug CLR 131.
  
8.1.10  Administration of CLR 131  
CLR 131 will be administered through a freely running peripheral IV catheter via a slow infusion of 
approximately 30 minutes duration. The dose of CLR  131 will be calculated for each patient based 
on total BSA (not to exceed 2.5 m2) calculated from actual body weight and height at screening.  
UW Hospi[INVESTIGATOR_357321]. All institutional policies will be followed in this study. The institution al policies will be followed in determining whether the CLR [ADDRESS_445901]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 52 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 52 done as an outpatient or inpatient. Suggested guidelines for monitoring for radioactivity and 
criteria to use for discharge are outlined in Section 10.1.  
 See the CLR  131 Radiopharmacy Manual (Supplementary Materials) for specific administration 
requirements . 
 The administration of CLR 131 is a research -related procedure.
 
8.1.11  Adverse Event Evaluation  
Adverse event assessment will be performed at screening  (standard of clinical care) ; at Day 1 
prior to each CLR 131 infusion  (research -related) ; weekly during EBRT  (research related) ; at 3, 6, 
and [ADDRESS_445902] EBRT  (standard of clinical care) ; and at the withdrawal  visit (research -related 
if applicable) . Adverse events will be assessed as described in Section [ADDRESS_445903]/CT  Imaging  
SPECT/CT imaging will be completed at two potential timepoints  after the CLR  [ADDRESS_445904] 
dose to evaluate for tumor uptake:  (a) approximately three days and (b) approximately [ADDRESS_445905]/CT scan on day 7- 8will be completed only if CLR 131 
uptake by [CONTACT_357365] 3 scan. Uptake in the specified site of recurrent/metastatic disease that is to be treated with radiation therapy will be determined by [CONTACT_357354].   
Subjects with demonstrated uptake on either SPECT/CT scan (day 3 or day 7) after the test dose 
and up to six subjects who do not demonstrate uptake of CLR [ADDRESS_445906]/CT imaging completed in order to visualize 
and quantitate the biodistribution of the CLR [ADDRESS_445907] /CT 
imaging scans, the Bednarz lab will utilize the Monte Carlo method to predict absorbed dose of CLR [ADDRESS_445908]/CT imaging , which is a research- related procedure, will be performed on days 2, 3, [ADDRESS_445909] CLR 131 treatment dose.  
8.1.13  Electrocardiogram (EKG)  
An EKG will be performed at the baseline/screening visit, as well as on the first day of treatment for EBRT.  This is a research- related procedure.  
8.1.14  Quality of Life Measures  
Quality of life (QoL) surveys will be collected at screening and at 3, 6, and [ADDRESS_445910] EBRT . 
The surveys are anticipated to take ~  20 minutes to complete.  
• SF-12  
• EORTC QLQ -C30 
• EORTC QLQ -H&N35  
• MDADI  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 53 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 53 • EAT-10 
• XeQoLS  
 
The completion of QOL  surveys is a research procedure.  
 Validated health outcome surveys will be used to assess subject  perception of mental and 
physical health, QOL , cancer -related H&N functioning, swallowing -related QOL and xerostomia 
before and after re- irradiation (Connor  et al. , 2006) . 
 Each subject  will serve as their own control with complete QOL evaluation prior to and following 
treatment. This will take into account various baseline dysfunctions that may be present from prior HNC therapy.  
 Perception of general health and QOL will be evaluated using the Medical Outcomes Trust Short Form 12 (SF -12) (Ware  et al. , 1995)  and the European Organization for Research and Treatment 
of Cancer Core Quality of Life Questionnaire (EORTC QLQ -C30) (Hammerlid  et al. , 2001; 
Hjermstad  et al. , 1995; Kemmler  et al. , 1999) . The SF -12 is a shorter version of the widely -used 
SF-36 and was chosen for its well -established acceptance as a valid and reliable measure of 
perception of physical and mental health across a large range of disease entities, including HNC (Gandek  et al. , 1998; Terrell  et al. , 1997; Terrell  et al. , 2004) . The EORTC QLQ -C30 was chosen 
for its sensitivity to cancer -related QOL and symptomatology, such as nausea/vomiting, fatigue 
and pain, and because it was identified previously as being well -developed, reliable, valid, and 
responsive (Ringash & Bezjak, 2001) . 
 Specific cancer -related H&N functioning will be assessed with the EORTC QOL Questionnaire 
H&N35 (EORTC QLQ -H&N35) (Bjordal  et al. , 1999; Sherman  et al. , 2000) . This validated 
instrument incorporates items related to swallowing, eating, dry mouth, and saliva production and 
is sensitive to cancer site and stage (Bjordal  et al. , 1999) . The EORTC QLQ -C30 and QLQ -
H&N35 will be administered together and will yield a global health status score.  
 
The MD Anderson Dysphagia Inventory (MDADI) and Eating Assessment Tool (EAT -10) will be 
used to investigate swallow- related QOL (P. H. Chen  et al. , 2009; Rosenthal  et al. , 2007; 
Rosenthal  et al. , 2008)  and the Xerostomia- related QOL scale (XeQoLS) will be used to measure 
subject -perceive d dry mouth and its implications for QOL (Henson  et al. , 2001; Rogers  et al. , 
2010) . 
8.1.[ADDRESS_445911] EBRT. This is a research procedure which will take ~[ADDRESS_445912]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 54 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 54 Saliva  (unstimulated and stimulated)  and saliva flow rates will be collected. Guidelines for 
collecting unstimulated and stimulated saliva developed by [CONTACT_357366] 
(USC) School of Dentistry (Navazesh & Kumar, 2008)  will be  adapted and used in this project. 
Unstimulated whole saliva production will be collected first for each subject, followed by [CONTACT_357367] a sample of stimulated saliva (Dawes, 
1987; Logemann  et al. , 2001) . Salivary compositional  analyses will focus on qualitative aspects of 
saliva previously found to change following radiation treatment: salivary viscosity (Sim et al. , 2018; 
Tolentino Ede et al. , 2011) , pH (Chitra & Shyamala Devi, 2008; Sim  et al. , 2018) , total protein 
concentration (mg/mL)  (Richards  et al. , 2017; Valdez  et al. , 1993) , amylase (mU/mL)  (Almstahl  et 
al., 2001; Chitra & Shyamala Devi, 2008) , mucin (MUC5B, mU/mL)  (Almstahl  et al. , 2001; Dijkema 
et al. , 2012)  and alpha and beta microbiota diversity (Hu et al. , 2013) . 
At the same time as saliva collection, a mucositis grade will be determined by [CONTACT_357368] (WHO) Oral Mucositis Assessment Scale. Also, the study team will grade oral health using the Kayser -Jones Brief Oral Health Status Examination 
(BOHSE), a valid and reliable scoring instrument developed for use with older adults by [CONTACT_105]-dental health care providers  (Kayser- Jones  et al. , 1995) . 
 
8.1.16  Oral profile  exam (research procedure)  
Subjects will participate in an  oral exam which will involve the following measurements: residual 
mucosal saliva ( RMS ), resting swallow frequency, maximum expi[INVESTIGATOR_27111], peak airflow 
during voluntary cough, and maximum lingual pressures. Oral exams will occur during the 
screening and at the [ADDRESS_445913] EBRT  visits . This is a research procedure which is 
estimated to take a total of 15- 20 minutes per visit .  
[IP_ADDRESS]  Residual Mucosal Saliva ( RMS ) 
RMS, which correlates with hyposalivation and dryness perception, will be collected from the 
anterior hard palate (AHP), buccal (BUC), anterior tongue (AT), and lower labial (LL) surfaces 
using SialoPaper strips (Oraflow Inc., Smithtown, NY, [LOCATION_003]). These strips will be applied for 10 seconds and measured using Periotron device (Oraflow Inc.).  
[IP_ADDRESS]  Resting  swallow frequency  
Resting swallow frequency  will be measured with combined methods: respi[INVESTIGATOR_357322], motion sensor around neck, and visual observation by [CONTACT_3647].   
[IP_ADDRESS]  Maximum Expi[INVESTIGATOR_357323] (MEP)   
Digital manometers will measure MEPs (cm H 2O) as a measure of expi[INVESTIGATOR_357324].  The MEP will be calculated as the best of three trials within 10 % variance.   
[IP_ADDRESS]  Peak airflow during voluntary  cough (PCF)  
Peak airflow during voluntary cough (PCF) will be measured using a peak airflow meter (Mini Wright Peak Flow Meter). Participants will be asked to inhale to total lung capacity (TLC) and to 
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 55 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 55 “cough hard like there is something stuck in the throat” while standing. The PCF will be calculated 
as the best of three trials within 10 % variance.  
[IP_ADDRESS]  Maximum  Lingual Pressures  (MLP) 
Participants will have maximum lingual pressures measured using an Iowa Oral Performance Instrument (IOPI).  Participants will press as hard as they can with their tongue against a pressure bulb positioned between the tongue and hard palate.  
8.1.17  Modified Barium Swallow Study  
Modified barium swallow (MBS) studies will be performed at screening,  [ADDRESS_445914] clinical procedure being done within routine care guidelines . The 
procedures below are detailed for the purposes of this study to control for consistent treatment 
within this study group.   
All subjects  will be examined using videofluoroscopy  (Supplemental Materials) . Each subject will 
be seated in the lateral plane while radiographic images of bolus swallows are captured in continuous acquisition mode keepi[INVESTIGATOR_357325].  
 Subject s will swallow pre -measured mL boluses of thin liquid barium. Other consistencies 
assessed will include nectar and honey thick barium liquids, puree (pudding) thick barium, mechanical soft and regular solids, including a pi[INVESTIGATOR_4382] (barium capsule) and a shortbread cookie coated with pudding- thick barium.  
 Evaluation measures were chosen because similar measurements have been shown to be sensitive to hyposalivation (Rogus -Pulia & Logemann, 2011) .  
 Our ability to assess and measure parameters related to swallowing is demonstrated by [CONTACT_357369]  (List et al. , 1996a; List  et al. , 1990; List  et al. , 1996b) . In addition to the videofluoroscopic 
swallowing assessments, diet will be rated using the Performance Status Scale (PSS) Normalcy 
of Diet Rating  and the Functional Oral Intake Scale (FOIS) .  
 
To perform the rated measures, such as oral residue  and Dynamic Imaging Grade of Swallowing 
Toxicity (DIGEST) scores, video recordings for all subjects at all timepoints will be presented in 
random order to two trained raters, who will be speech- language pathologists who specialize in 
swallowing and were not involved in the data collection. Ten percent of samples will be included twice to measure intra- rater reliability. To encourage adequate inter -rater reliability, raters will view 
a training sequence that does not include test items and provides anchors for each parameter until 90 % agreement is reached. Any occurrences of penetration or aspi[INVESTIGATOR_357326] (Robbins  et al. , 1999; Rosenbek  et al. , 1996) . 
8.1.[ADDRESS_445915], MR, or PET -MR scans, as clinically 
indicated. If cross sectional imaging is unable to be obtained, other imaging modalities may be 
used (see section 9.3). The imaging study performed at screening should be repeated at 
subsequent assessments.  
 Imaging studies are standard clinical care  procedures being done within routine care guidelines.  
8.2 Laboratory Procedures/Evaluations  
Laboratory testing will be completed by [CONTACT_84905] -certified labs .  
8.2.1  Clinical Laboratory  Evaluations  
[IP_ADDRESS]  Complete Blood Count with Differential  
Blood will be drawn for CBC with differential at screening (standard of clinical care); weekly for 12 
weeks beginning with day 1 treatment dose  (research -related procedure); and at [ADDRESS_445916] 
EBRT  (standard of clinical care) .  
The CBC will include red blood cell count, hemoglobin, hematocrit, WBC count with differential including % neutrophils, lymphocytes, monocytes, eosinophils and basophils, absolute neutrophil count, and platelet count.  
[IP_ADDRESS]  Serum Chemistries  
Blood will be drawn for serum chemistries at screening, weekly for [ADDRESS_445917] procedure being done 
for research- related purposes of radiotherapeutic administration.  
 The serum chemistries will include sodium, potassium, chloride, bicarbon ate, blood urea nitrogen 
(BUN) , creatinine, glucose, aspartate aminotransferase (AST) , alanine aminotransferase  (ALT), 
alkaline phosphatase, total bilirubin, calcium, protein, albumin , and phosphorus . 
[IP_ADDRESS]  Pregnancy Test  
A urine pregnancy test will be completed within [ADDRESS_445918] 1 year or surgically 
sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be of childbearing potential .  
 Pregnancy testing is being done as part of standard clinical care.  
[IP_ADDRESS]  Thyroid Function Tests  
Blood will be drawn for serum analysis of TSH and free T4 at screening; 3, 6, and [ADDRESS_445919] -completion of the EBRT portion of the protocol – see study 
calendar.  Only those subject s who receive a treatment dose of study drug will be assessed for 
response and/or progression. Those with inadequate uptake after the dosimetry  test dose will only 
be followed for safety measures.  
  
Response and progression will be evaluated in two distinct fashions. For those without evidence 
of metastatic disease at the time of study enrollment, response and progression will be evaluated 
using the new international criteria proposed by [CONTACT_8225] 
(RECIST) 1.1 Committee  (Eisenhauer  et al. , 2009) .  
 
For those with metastatic disease at the time of study enrollment, study lesions will be defined 
within the locoregional recurrence field that will be receiving EBRT. Those lesions will be assessed for response and progression using RECIST 1.[ADDRESS_445920] s will be censored as having disease progression, regardless 
of the status of the locoregional target lesions.  
Note: Lesions are either measurable or non- measurable using the criteria provided below.  
9.[ADDRESS_445921] one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques (CT, MRI, x-ray) or as > [ADDRESS_445922] be recorded in 
millimeters (or decimal fractions of centimeters) . To be considered pathologically enlarged and 
measurable, a lymph node must be ≥ [ADDRESS_445923] scan.  
9.2 Non-measurable Disease  
All other lesions (or sites of disease), including small lesions (longest diameter  
< 20 mm with conventional techniques or < [ADDRESS_445924] scan or pathological lymph nodes with ≥ 10 to < 15 mm short axis), are considered non- measurable disease. Bone lesions, 
leptomeningeal disease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory breast disease, abdominal masses (not followed by [CONTACT_462]), and cystic lesions are all non- measurable.  
9.[ADDRESS_445925]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 58 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 58 Note:  Tumor lesions that are situated in a previously irradiated area can be considered 
measurable only if there is documented growth of the lesion, and at least [ADDRESS_445926] of a treatment.   
Clinical lesions:  Clinical lesions will only be considered measurable when they are superficial 
and ≥ 10 mm diameter (e.g., skin nodules and palpable lymph nodes). In the case of skin lesions, documentation by [CONTACT_6775], including a ruler to estimate the size of th e lesion, is 
recommended.  
Chest x- ray: Lesions on chest x -ray are acceptable as measurable lesions when they are clearly 
defined and surrounded by [CONTACT_6776]. However, CT is preferable.  
Conventional CT and MRI:  These techniques should be performed with cuts of [ADDRESS_445927], abdomen, and pelvis. Head and neck tumors  and those of extremities usually require specific protocols.  
Ultrasound:  When the primary endpoint of the study is objective response evaluation, US should 
not be used to measure tumor lesions. It is, however, a possible alternative to clinical measurements of superficial palpable lymph nodes, subcutaneous lesions, and thyroid nodules. 
Ultrasound might also be useful to confirm the complete disappearance of superficial lesions 
usually assessed by [CONTACT_12148].  
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation has 
not yet been fully and widely validated. Their uses in this specific context require sophisticated equipment and a high level of expertise that may only be available in some centers. T herefore, the 
utilization of such techniques for objective tumor response should be restricted to validation purposes in reference centers. However, such techniques may be useful to confirm complete pathological response when biopsies are obtained.  
 
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 59 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 59 10 RADIATION SAFETY  
10.1 Radiation Safety Monitoring and R elease Criteria  
UW Hospi[INVESTIGATOR_357327]/policy regarding the release criteria following 
administration of radioactive material. All institutional policies will be followed in this study . The 
guidelines below are recommendations only, and the regulations of the institution will take precedence.  
  
Prior to the initiation of this trial, the Radiation Safety Officer will be contact[CONTACT_357370]. The institution’s Radiation 
Safety Officer will conduct all appropriate training of research staff.  
 Sponsor suggested guidelines for monitoring for radioactivity and criteria to use for discharge are:  
 
• Starting one day after the CLR 131 infusion, medical physics/radiation oncology personnel will 
monitor subject  radiation levels at 1 meter from umbilicus.  
• Subject s will be discharged from the hospi[INVESTIGATOR_357328] < 7 mrem/hr and the 
discharge is cleared by [CONTACT_357371].  
10.[ADDRESS_445928]  Radiation Precautions  
Prior to the initiation of this trial, the Radiation Safety Officer will be contact[CONTACT_357372]. The Radiation Safety Officer will perform all appropriate training of research staff.  
 Written instructions, approved by [CONTACT_8236]’s Radiation Safety Officer, describing methods to limit radiation dose to others must be given to the subject  prior to CLR  131 infusion. The following 
precautions, conservatively derived from recommendations of the Society of Nuclear Medicine and Molecular Imaging  (Silberstein  et al. , 2012)  and the American Thyroid Association Taskforce 
on Radioiodine Safety, 2011, are suggested for subjects following the administration of CLR  131 
to lessen the risk to others:  
For three weeks  after each dose of CLR  131: 
• Sleep alone and abstain from intercourse  
• Do not sleep with infants, small children or pregnant women for three weeks after CLR 131 infusion  
For one week  after each dose of CLR  131:  
• Avoid participating in feeding, clothes changing and similar care of infants and small children  
• Limit time with and maintain a distance of approximately 3- 6 feet from pregnant 
women and children  
• Do not prepare food for others that requires prolonged handling with bare hands  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 60 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 60 • Do not share dishes, utensils, towels or face cloths with others prior to washing  
• Do not share razors, toothbrushes, food or drinks with others  
• Flush toilet twice after use and wash hands for 20 seconds afterwards. Men should 
urinate sitting down.  
• Rinse the sink and wash hands thoroughly after brushing teeth  
• Do not stay in a location other than a private residence (such as a hotel)  
• Limit the time spent in public places to 1- [ADDRESS_445929] from others may not always be possible  
• Bathe/shower daily for at least three days after CLR 131 infusion  
• Avoid prolonged use of public transportation the first day after CLR [ADDRESS_445930] step is to identify the event using the Common Terminology Criteria for Adverse Events (CTCAE). The CTCAE document provides descriptive 
terminology for adverse event reporting. A grading (severity) scale is provided for each adverse event term.  
 
All AEs, whether serious or not, will be described in the source documents and the AE page of the 
Case Report Form ( CRF). All new events, as well as those that worsen in intensity or frequency 
relative to baseline, that occur after administration of study drug through the period of protocol -
specified follow -up must be captured.  
Specific anticipated adverse events are described in section 2.3.  
Information to be reported in the description of each AE includes but is not limited to:  
• Medical diagnosis of the event. (If a medical diagnosis cannot be determined, a description of each sign or symptom characterizing the event should be recorded.)  
• The date of onset of the event  
• The date of resolution of the event  
• Whether the event is serious or not  
• Action taken  
• Outcome  
• Relatedness to the study drug (see below)  
• Subject ’s condition is intermittent or continuing 
• The grade of the event based on the CTCAE v5.[ADDRESS_445931]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 62 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 62 11.1.1  Unanticipated Problems  
The Office for Human Research Protections (OHRP) considers unanticipated problems involving 
risks to subjects or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:  
• unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol -related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the subject population being studied;  
• related or possibly related to participation in the research ( “possibly related”  means there is 
a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and  
• suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
11.1.[ADDRESS_445932] , 
including any abnormal sign (for example, abnormal physical exam or laboratory finding), 
symptom, or disease , temporally associated with the subject’s participation in the research, 
whether or not considered related to the subject’s participation in the research.  
11.1.3  Serious Adverse Events (SAE)  
A serious adverse event is defined as any adverse event that meets one of the following criteria:  
• Results in death; OR  
• Is life -threatening; OR  
• Requires hospi[INVESTIGATOR_72010]; OR  
• Results in significant or persistent disability or incapacity; OR  
• Results in a congenital anomaly/birth defect  
Planned hospi[INVESTIGATOR_357329]- related surgery, routine procedures, non –disease -related 
procedures, and inpatient hospi[INVESTIGATOR_357330]/exposure levels are not considered SAEs.  
11.[ADDRESS_445933]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 63 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 63 of AE/SAEs since the last visit . Events will be followed for outcome information until resolution or 
stabilization.  
11.2.1  Adverse Events  
• AEs will be recorded from time of informed consent until [ADDRESS_445934] treatment dose  of CLR 131, which ever is later.  
• AEs will be recorded per the reporting time above regardless of whether or not they are considered related to the study drug(s).  
• AEs will be recorded in the subject’s medical record and on the appropriate study specific eCRF form within OnCore.  
• All AEs considered related to study drug(s) will be followed until resolution to ≤ Grade 1 or baseline, deemed clinically insignificant, and/or until a new anti -cancer treatment starts, 
whichever occurs first.  If the subject begins a new anticancer therapy, the AE reporting period 
for non- serious AEs ends at the time the new treatment is started.  
• Only clinically significant laboratory abnormalities  will be captured as adverse events on the 
appropriate study specific eCRF form within OnCore.  
11.2.2  Serious Adverse Events 
• SAEs , both related or unrelated to the study,  will be recorded from time of informed consent 
until [ADDRESS_445935] treatment dose  of CLR 131, 
which ever is later.  
• Any SAEs experienced after this period will only be reported if the investigator suspects a 
causal relationship of possibly, probably or definitely related to the study treatment.  
• SAEs will be reported on the SAE Submission Form and entered in SAE tab in OnCore within the timeframe listed in Table 2 .  
• SAEs will be recorded in the subject’s medical record and on the appropriate study specific eCRF form within OnCore.  
• All SAEs, regardless of relation to study drug, will be followed until resolution to ≤  Grade 1 or 
baseline and/or deemed clinically insignificant and/or until a new anti -cancer treatment starts, 
whichever occurs first.  
• Recurrent epi[INVESTIGATOR_1841], complications, or progression of the initial SAE will be reported as follow -
up to the original epi[INVESTIGATOR_5319] [ADDRESS_445936]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 64 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 64 Table 1: Other Reportable Events Timeframe  
Event  Definition  Reporting  
Breach of 
confidentiality  The exposure of any study information or 
communications directly related to a study subject to 
anyone not named as study staff or the release of a 
study subject’s identifiable information to study staff who 
were not specified to receive such information in the 
protocol or IRB application.  Within [ADDRESS_445937] of the study. 
Deviations may result from the action of the participant, 
investigator, or staff.  See details below  
Major deviations  Deviations are considered major when the unapproved 
change(s) in previously approved research activities, 
implemented without IRB approval, may potentially 
adversely affect subjects’ rights, safety, welfare, or 
willingness to continue participation, or aff ect the 
scientific design of the study and/or the integrity of the 
resultant data.  Within 14 business days 
of knowledge of event  
Minor deviations  Deviations are considered minor when the unapproved 
change(s) in previously approved research activities, implemented without IRB approval, do not adversely 
affect subjects or the integrity of the study data.  Cumulative minor 
deviations are reported at the time of continuing 
review.  
Protocol 
violation  An incident involving an intentional deviation from the 
IRB-approved protocol that was not implemented in 
response to an emergency situation and that may impact 
a subject’s rights, safety, and/or welfare, makes a 
substantial alteration to risks to subjects , or affects the 
scientific design of the study and/or the integrity of the resultant data. Violations may also be repeated 
deviations (major or minor) of the same nature. 
Violations can represent serious or continuing non-
compliance with the federal regul ations and guidelines 
for ethical conduct of human subject research.  Within [ADDRESS_445938]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 65 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 65 11.3 Characteristics of an Adverse Even t 
11.3.1  Relationship to S tudy Intervention 
The PI [INVESTIGATOR_357331]:  
• Definite = AE is definitely related to the study procedures  
• Probable = AE is likely related to the study procedures  
• Possible = AE is possibly related to the study procedures  
• Unlikely = AE is doubtfully related to the study procedures  
• Unrelated = AE is definitely not related to the study procedures  
11.3.[ADDRESS_445939] treatment dose of CLR 131. Thus, 
the DLT period has been defined to account for the expected toxicities of CLR  131 in section 
[IP_ADDRESS].1  
There are expected significant toxicities and adverse events associated with SOC EBRT. These 
toxicities include Grade 3 radiation mucositis and Grade 3 radiation dermatitis.   
11.3.3  Severity of Event  
Adverse events will be documented and recorded at each visit using NCI CTCAE version 5.0.  
11.4 Reporting Procedures  
11.4.1  Unanticipated Problem (UP) Reporting to IRB , Cellectar  and UWCCC DSMC  
Incidents or events that meet the OHRP criteria for unanticipated problems require the creation and completion of an unanticipated problem report form . OHRP recommends that investigators 
include the following information when reporting an adverse event, or any other incident, experience, or outcome as an unanticipated problem to the IRB:  
• appropriate identifying information for the research protocol, such as the title, investigator’s name, and the IRB project number;  
• a detailed description of the adverse event, incident, experience, or outcome;  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 66 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 66 • an explanation of the basis for determining that the adverse event, incident, experience, or 
outcome represents an unanticipated problem;  
• a description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the unanticipated problem.  
To satisfy the requirement for prompt reporting, unanticipated problems will be reported using the following timeline:   
• Unanticipated problems that are serious adverse events will be reported to the IRB , 
Cellectar  Biosciences ([EMAIL_6887] ) and to the UWCCC DSMC per Table 2 
timeline.  
• Any other unanticipated problem will be reported to the IRB , Cellectar  Biosciences  
([EMAIL_6887] ) and the UWCCC DSMC per Table 1 timeline.   
• All unanticipated problems should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written reporting procedures), the supporting agency head (or designee), and OHRP within one month of the IRB’s receipt of the report of t he problem 
from the investigator.  
11.4.[ADDRESS_445940] also be reported to 
the UW IRB (if applicable), and any sponsor/funding agency not already included in the list.  
 
SAEs experienced by a subject after the active reporting period has ended should be reported to Cellectar Biosciences  if the PI  [INVESTIGATOR_357332]; at a minimum, all SAEs that the PI 
[INVESTIGATOR_357333] a reasonable possibility of being related to investigational product are to be reported to Cellectar Biosciences . 
 Determine the reporting time line for the SAE in question by [CONTACT_15275].
  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 67 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 67 Table 2: FDA Reporting Requirements.  
FDA Reporting Requirements for Serious Adverse Events (21 CRF Part 312)  
NOTE:  Investigators MUST  immediately report to the UWCCC DSM C, Cellectar Biosciences, and 
the IRB (if applicable)  and any other parties outlined in the protocol  ANY Serious Adverse Events, 
whether or not they are considered related to the investigational agent(s)/intervention (21 CFR 
312.64).  
An adverse event is considered serious if it results in ANY of the following outcomes:  
1) Death.  
2) A life- threatening adverse event (the subject  was at risk of death at the time of the event; it 
does not refer to an event that hypothetically might have caused death if it were more severe).  
3) An adverse event that results in inpatient hospi[INVESTIGATOR_9959] ≥ 24 hours.  * 
4) A persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions.  
5) A congenital anomaly/birth defect.  
6) Important Medical Events (IME) that may not result in death, be life threatening, or require 
hospi[INVESTIGATOR_708], based upon medical judgment, they may 
jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition (FDA, 21 CFR  312.32; ICH E2A and ICH E6).  
ALL SERIOUS  adverse events that meet the above criteria MUST  be immediately reported to 
Cellectar and UWCCC DSMC  within the timeframes detailed in the table below:   
Hospi[INVESTIGATOR_15164] 1 and Grade 2 Timeframes  Grade 3-5 Timeframes  
Resulting in hospi[INVESTIGATOR_059] ≥  
24 hrs 10 Calendar Days  
24 Hour; 5 Calendar Days  
Not resulting in 
Hospi[INVESTIGATOR_059] ≥ 
[ADDRESS_445941]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 68 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 68  
*Planned hospi[INVESTIGATOR_357329] -related surgery, routine procedures  (such as G -
tube placement) , non– disease- related procedures, and inpatient hospi[INVESTIGATOR_357334]/exposure levels are not considered SAEs.  A hematologic adverse 
event grade 1- [ADDRESS_445942] 
transfusions, unless it exceed s the window for a dose limiting toxicity.  
 
Expedited AE reporting timelines are defined as:  
• 24-Hour; 5 Calendar Days – The AE must initially be reported within 24 hours of learning of 
the AE, followed by a complete expedited report within 5 calendar days of the initial 24-hour 
report.  
• 10 Calendar Days – A complete expedited report on the AE must be submitted within [ADDRESS_445943] an attribution of possible, probable, 
or definite require reporting as follows:  
Expedited 24-hour notification followed by [CONTACT_432] 5 calendar days for:  
• All Grade 3, 4, and 5 AEs  
Expedited 10 calendar day reports for:  
• Grade 2 AEs resulting in hospi[INVESTIGATOR_318]  
[IP_ADDRESS]  Reported within 24 Hours  
Serious Adverse Events requiring reporting within 24 hours (as described above) must also be 
reported to the UWCCC DSMC  within one business day. See [IP_ADDRESS].1.1. SAEs will also be 
reported to Cellectar Biosciences  within [ADDRESS_445944] be submitted along with other report materials as appropriate (FDA Medwatch 
Form #3500 and/or any other documentation available at that time of initial reporting) . Within [ADDRESS_445945] be submitted electronically along with a 24 hour follow -up SAE Details Report and a completed UWCCC SAE Routing Form to 
[EMAIL_259]. All follow up SAE documentation will also be submitted to Cellectar Biosciences  ([EMAIL_6887]) . All information is entered and tracked in the 
UWCCC database.  
 
The Principal Investigator [INVESTIGATOR_357335], the IRB, 
and Cellectar Biosciences . 
[IP_ADDRESS].1  Report to the UWCCC , and Cellectar Biosciences : 
Reference the SAE SOP  (Standard Operating Procedure) and the SAE Reporting Workflow for 
DOTs  on the UWCCC website (http://kb.wisc.edu/uwccc) for specific instructions on how and what 
to report to the UWCCC for [24] hour initial and follow -up reports . A follow- up report is required 
to be submitted within 10 days of the initial [24] hour report.  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 69 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 69  
For this protocol, the following entities are required to be notified:  
a. [EMAIL_259]  
b. UWCCC PIs: Justine Yang Bruce, MD and Paul Harari, MD  
c. UWCCC PM: Diana Trask  
d. Cellectar Biosciences ( [EMAIL_6887] ) 
e. Medpace: medpace- [EMAIL_1925]  
f. Any other appropriate parties listed on the SAE Routing Form (for follow -up reports only)  
[IP_ADDRESS].2  Report to the IRB  
Consult the UW -IRB website for reporting guidelines.  
[IP_ADDRESS]  Reported within 10 Calendar Days  
Serious Adverse Events requiring reporting within 10 calendar  days (as described above) must 
also be reported to the Data and Safety Monitoring Board (DSMC ) Chair via an email to 
[EMAIL_259]. SAEs will also be reported to Cellectar Biosciences . The OnCore 
SAE Details Report must be submitted along with other report materials as appropriate (FDA Medwatch Form #3500 and/or any other documentation available at the time of initial reporting). The UWCCC DSMC Chair will review the information and  determine if further action is required. 
All information is entered and tracked in the UWCCC database.  
The Principal Investigator [INVESTIGATOR_357335], the IRB, and Cellectar Biosciences .  
[IP_ADDRESS].1  Report to the UWCCC  and  Cellectar Biosciences : 
Reference the SAE SOP  and the SAE Reporting Workflow for DOTs  on the UWCCC website 
(http://kb.wisc.edu/uwccc ) for specific instructions on how and what to report to the UWCCC for 
[10] day reports.   For this protocol, the following entities are required to be notified:  
a. [EMAIL_259]  
b. UWCCC PIs: Justine Yang Bruce, MD and Paul M. Harari, MD  
c. UWCCC PM: Diana Trask  
d. Cellectar Biosciences ( [EMAIL_6887] ) 
e. Medpace: medpace- [EMAIL_1925]  
f. Any other appropriate parties listed on the SAE Routing Form (for follow -up reports only)  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 70 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 70 [IP_ADDRESS].2  Report to the IRB:  
Consult the UW -IRB website for reporting guidelines.  
11.4.[ADDRESS_445946] information:  
US:  Phone: 1 -[PHONE_2257], dial 3  
Or      [PHONE_2261], dial 3  
FAX:  1 -[PHONE_4987]  
  Or    1--866- 336-5320  
 
Email: Medpace- [EMAIL_1925]  
 
11.4.4  Reporting of Pregnancy  
• Pregnancy will be reported from time of first study drug until 85  days after discontinuation of 
CLR 131. 
• Pregnancy will be reported to UW within [ADDRESS_445947] on study treatment will be reported to UW 
within 1 business day of learning of its occurrence. The pregnancy will be followed to determine 
outcome, including spontaneous or voluntary termination, detail s of the birth, and the presence or 
absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications.  
11.[ADDRESS_445948] of this study, adverse events and serious adverse events that are categorized as probably related  to CLR 131 will be evaluated and analyzed weekly by [CONTACT_221098].  If >25 % of subjects have serious adverse events that are probably related to 
CLR [ADDRESS_445949]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 71 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 71 12 STUDY  OVERSIGHT  
The UWCCC Data and Safety Monitoring Committee (DSMC) is responsible for the regular 
review and monitoring of ongoing clinical research in the UWCCC.  A summary of DSMC 
activities are as follows:  
• Review clinical trials conducted at the UWCCC for subject safety, protocol compliance, and 
data integrity.  
• Review Serious Adverse Events (SAE) requiring expedited reporting, as defined in the protocol, for clinical trials conducted at the UWCCC, and studies conducted at external sites for which the UWCCC acts as an oversight body.  
• Review reports generated through the UWCCC DSMS elements (Internal Audits, Quality Assurance Reviews, Response Reviews, Compliance Reviews, and Protocol Summary Reports).  
• Notify the protocol Principal Investigator [INVESTIGATOR_164360], if applicable, any requirements for corrective action related to data or safety issues.  
• Work in conjunction with the UW Health Sciences IRB in the review of relevant safety information as well as protocol deviations, non- compliance, and unanticipated problems 
reported by [CONTACT_15266], when appropriate.  
• Ensure notification of SAEs which require expedited reporting are provided to external sites participating in multi -institutional clinical trials coordinated by [CONTACT_135262].  
Monitoring and Reporting Guidelines  
UWCCC quality assurance and monitoring activities are determined by [CONTACT_357373]. All protocols (including Intervention Trials, Non-Intervention Trials, Behavioral and Nutritional Studies, and t rials conducted under a Training 
Grant) are evaluated by [CONTACT_15269]. UWCCC monitoring requirements for trials without an acceptable external DSMB are as follows :
 
Intensive  Monitoring 
Protocols subject to intensive monitoring generally include UW Institutional Phase I . These 
protocols undergo review of subject safety at regularly scheduled DO T meetings where the results 
of each subject’s treatment are discussed,  and the discussion is documented in the DO T meeting 
minutes. The discussion includes the number of subjects enrolled, significant toxicities, dose adjustments, and responses observed. Protocol Summary Reports are submitted on a quarterly  
basis by [CONTACT_357374] C DSM C. All reports from the UWCCC DSM C will be 
provided to Cellectar Biosciences .  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 72 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 72 Review and Oversight Requirements  
 
• Study Progress Review  
o Protocol Summary Reports (PSR) are required to be submitted to UWCCC DSM C 
quarterly . The PSR provides a cumulative report of SAEs, as well as instances of 
noncompliance, protocol deviations, and unanticipated problems, toxicities and 
responses that have occurred on the protocol in the timeframe specified. PSRs for those protocols scheduled for review are reviewed at each DSM C meeting.  
o Protocol Summary Reports enable DSM C committee members to assess whether 
significant benefits or risks are occurring that would warrant study suspension or closure. This information is evaluated by [CONTACT_9288] C in conjunction with other reports of 
quality assurance activities (e.g., reports from Internal Audits, Quality Assurance 
Reviews, etc.) occurring since the prior review of the protocol by [CONTACT_9288] C.  
o In the event that there is significant risk warranting study suspension or closure, the  
UWCCC DSM C will notify the PI [INVESTIGATOR_357336] (e.g., suspension or closure). The DSM C ensures that the PI 
[INVESTIGATOR_15161] a clinical trial to the appropriate agencies. Any UWCCC DSM C findings and requirements for follow -up action are 
submitted to the UWCCC CRC.  
 
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 73 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 73 13 CLINICAL  SITE MONITORING  
Cellectar Biosciences or their designee may periodically monitor the data for the study. A clinical 
monitor will make regularly scheduled trips to the clinical sites to review the progress of the study. The actual frequency of monitoring trips will depend on the enrollment rate and performance at the site. At each visit, the monitor will review various aspects of the study including, but not limited to, screening and enrollment logs, compliance with the protocol and with the principles of ICH GCP, completion of CRFs, source data verification, and study drug accountability and storage.  
In addition to the above, a representative from Cellectar Biosciences’ auditing staff or government inspectors may review the conduct/results of the study at the clinical site. The Investigator must promptly notify Cellectar Biosciences of any audit reques ts by [CONTACT_12721].  
 
 
Cellectar                                                                                  04Oct  [ADDRESS_445950]  specific symptoms, such as quality of life , 
salivary flow and swallowing function.   
14.2 Sample Size Considerations  
An mTPI -2 design, an extension of modified toxicity probability interval (mTPI -2), will be used to 
identify the MTD using cohorts of 4 subjects and up to 3 dose levels of CLR 131(Ji  et al. , 2007; Ji 
& Wang, 2013) . The first [ADDRESS_445951] s treated at a dose level will be 8, with one exception: if [ADDRESS_445952] s in cohort recover 
to non- DLT levels or meet the criteria above. If 0 out of 4 subjects experiences a DLT at Dose 
Level 2, the study will move directly to the expansion phase.  
 
 
Dose Level  Dose s* of CLR 131 
-1 12.5 mCi/m2 
    1** 15.6 mCi/m2 
2 18.75 mCi/m2 
*Dose level listed is administered on first on day 1 and again on day 8.  
**The first [ADDRESS_445953]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 75 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 75 Table 3: Dose escalation rules 
  [ADDRESS_445954] s with DLTs . E: Escalate to the 
next higher dose; S: Stay at the same dose; D: De-escalate to the previous lower dose; DU: De-escalate to the 
previous lower dose and the current dose will never be used again in the trial; sample size = 10, target toxicity 
probability = 0.2, epsilon 1 = 0.1, epsilon 2 = 0.1. 
 
The number of participants treated in the expansion cohort is dependent on the number of participants treated at the MTD in the dose escalation phase using the the mTPI -2 design. Up to 
12 subjects will be treated at the MTD. Statistical analysis for outcom es is based on participants 
treated at the MTD, including dose escalation patients treated at the MTD .
 
 
In recent years, the head and neck oncology program at UW has evaluated approximately 75- 100 
patients per year with recurrent HNC. We estimate that approximately half of these patients would be potential candidates for this trial. Assuming enrollment of 50  % of eligible patients, and 
CLR 131 uptake in 75 % of subject s administered a  dosimetry  test dose, we anticipate no 
problems to accrue the necessary subject s over [ADDRESS_445955] statistical methods (such as exact binomial confidence interval) due to small sample 
size.
 
14.3.[ADDRESS_445956]/CT imaging and Monte Carlo calculations will be reported. Quality of life measures  (including swallow function assessed by [CONTACT_357375]                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 76 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 76 QOL assessed by [CONTACT_357376])  will be analyzed using frequency tables and confidence intervals 
constructed using exact statistical methods (such as exact binomial confidence interval) or 
summary statistics. Comparison of continuous and categorical QOL measures before and after treatment will be descri bed using summary statistics and analyzed using the Wilcoxon signed rank 
test and McNemar’s test, respectively.  ORR will be reported as a proportion with an exact 
confidence interval. Stimulated salivary flow wi ll be reported before and after treatment using 
summary statistics.  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 77 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 77 15 SOURCE DOCUMENTS  AND ACCESS TO  SOURCE DATA/D OCUMENTS  
Study staff will maintain appropriate medical and research records for this study, in compliance 
with ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality of subjects. Study staff will permit authorized re presentatives of Cellectar 
Biosciences, and regulatory agencies to examine (and when required by [CONTACT_1289], to copy) 
research records for the purposes of quality assurance reviews, audits, and evaluation of the study safety, progress and data validity .  
Source documents will include all records within the HealthLink Electronic Medical Records system such as hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, pharmacy dispensing records, copi[INVESTIGATOR_357337], photographs or digital photo files, x -rays, and subject files and records kept at the 
pharmacy, at the laboratories, and medico- technical departments involved in the clinical trial. In 
addition, protocol specific for ms will be designed which require treating physician signature [CONTACT_357382].  Thi s may include forms such as toxicity forms with grading and 
attribution and tumor measurement forms.  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 78 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 78 16 QUALITY CONTROL AND QUALITY  ASSURANCE  
16.1 Monitoring, Auditing, and Data Quality Control and Assurance Measures   
All personnel involved in FDA regulated clinical trial activities are required to complete the Human 
Subjects Training and Good Clinical Practice (GCP)  via CITI every 3 years . Training is monitored 
at each IRB continuing review and with the submission of protocol amendments.  
At the protocol level, the Principal Investigators will assign and document protocol responsibilities based on study roles. Training on all IRB approved protocols (initial version and subsequent amendments) are documented for each person listed as key pers onnel on the University of 
Wisconsin Health Sciences IRB application. These documents are retained with the study regulatory files, and collection is coordinated by [CONTACT_236955].  
Eligibility checklists are signed by [CONTACT_357377]. Adverse event grading and attributions are assigned by [CONTACT_236957].  
Other relevant UWCCC SOPs include : 
• Adverse Event Assessment and Documentation_SOP  
• CTRP and ClinicalTrials.gov Reporting_SOP  
• Delegation of Authority Log_SOP  
• Informed Consent Process_SOP  
• Maintaining a Regulatory File_SOP  
• OnCore Data Quality Assurance_SOP  
• Protocol Deviation_Guidance  
• Reportable Events_SOP  
• Reporting of Serious Adverse Events (SAEs) at UWCCC, 1SP, JC, And Affiliate Sites_SOP  
• Source Documentation_SOP  
• Study Close Out_SOP  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 79 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 79 17 ETHICS /PROTECTION  OF HUMAN SUBJECTS  
17.[ADDRESS_445957]  
The investigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research , as drafted by [CONTACT_287531] (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6 .  
17.[ADDRESS_445958]  
The protocol, informed consent form(s), recruitment materials, and all subject materials will be submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be obtained before any subject is enrolled. Any amendment  to the protocol will require 
review and approval by [CONTACT_36159].
 
17.[ADDRESS_445959].  
17.4 Exclusion of Women, Minorities, and Children (Special Populations)  
Children are excluded from this study because insufficient data are available in adults to judge 
potential risks in children.  
Adults of any gender or racial/ethnic group may participate in this study.  
Cellectar                                                                                  04Oct  [ADDRESS_445960] by [CONTACT_473], study staff, and the sponsor(s) 
and their agents. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to any study information relating to subjects.  
All members of the study team will be listed on the IRB application and are required to undergo annual HIPAA training to ensure responsible conduct regarding protected health information (PHI) in research. In addition, Human Subjects Training and Good Clinical Practice trainings are required every three years for members of the study team.  
The study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.   All PHI is stored securely on password 
protected servers.  
The study monitor or other authorized representatives of the sponsor may inspect all study documents and records required to be maintained by [CONTACT_093], including but not limited to, medical records (office, clinic, or hospi[INVESTIGATOR_307]) for the study subjec ts. The clinical study site will permit 
access to such records.  
To further protect the privacy of study participants, the study team has applied for and received  a 
Certificate of Confidentiality (CoC) for this study from the FDA . A Certificate of Confidentiality 
prohibits study team members  from disclosing information or biospecimens that may identify study 
participants  in legal proceedings or in response to a legal request without their consent.  
17.[ADDRESS_445961] -specific study treatment calendars, adverse events and other 
information will be maintained with the UWCCC data management system.  
 Participant data will be collected using protocol specific case report forms (CRFs). The CRFs will be approved by [CONTACT_1758]’s Principal Investigator [INVESTIGATOR_236916]. The Study Coordinator or designee will be responsible for registering the subject  into the 
UWCCC data management system at time of study entry, completing CRFs based on the subject  
specific calendar, and updating the subject  record until subject  death or end of required study 
participation.  
18.[ADDRESS_445962] be reviewed by [CONTACT_1719].  
 UWCCC Radiotherapy will serve as the Clinical Research Office for this trial.  
18.2 Data Capture Methods  
Data will be collected through the web- based clinical research platform, OnCore (Forte Research), 
a system compliant with Good Clinical Practices and Federal Rules and Regulations. UWCCC personnel will coordinate and manage data for quality control assurance and integrity. All data will be collected and entered into OnCore by [CONTACT_26271]. We will also utilize REDCap for 
Biospecimen tracking purposes. The data in REDCap will be coded, and no subject identifiers will be stored in the Biospecimen REDC ap Database.  
18.[ADDRESS_445963]  specific study treatment calendars, 
adverse events, laboratory/pathology reports obtained during the course of treatment and afterwards, e.g., blood tests, biopsy results), findings from physical exams, and imaging scan reports/outcomes will be maintained  within the UWCCC data management system.  
18.4 Schedule and Content of Reports  
The UWCCC Protocol Review and Monitoring Committee (PRMC) determines the level of risk, thus the appropriate timelines for review of study documents, conduct and accrual.  Protocol Safety Reports are run, reviewed and signed off by [CONTACT_9154] [INVESTIGATOR_357338]. 
PSRs are then sent for review to the Data Safety Monitoring Committee  (DSM C).   
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 82 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 82 Protocol Safety Reports include information such as accrual, adverse events, serious adverse 
events, and unanticipated problems. Annual review by [CONTACT_357378], reportable events, and study progress.  
18.5 Study Records Retention  
Shadow research charts with original consent forms and documents specifically created for this 
study will be maintained in the Department of Human Oncology until the study is terminated.  The records will then be sent to Wisconsin State Records Archiving f acility for long term storage (10 
years) and re- archived as needed. Study records will be maintained for at least three years from 
the date that the grant federal financial report (FFR) is submitted to the NIH.  
18.[ADDRESS_445964] s’ best interest. The investigator has to contact [CONTACT_357379] a subject may cont inue in the study when a protocol violation out of medical reasons has 
occurred.  Protocol deviations that are not identifiable from the eCRF have to be recorded in a 
protocol deviation form. Protocol deviations will be evaluated at the data review meeting before database lock and will be described in the statistical analysis plan.  
All deviations must be addressed in study source documents and reported to the UW HS IRB per their policies  using Table [ADDRESS_445965]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 83 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 83 19 PUBLICATION/ DATA SHARING  POLICY  
This study will comply with the NIH Public Access Policy , which ensures that the public has 
access to the published results of NIH funded research. It requires scientists to submit final peer -
reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central  
upon acceptance for publication.  
The clinical trial will be registered on ClinicalTrials.gov , which is sponsored by [CONTACT_10418].  
The study investigators will have sole right to determine the content of the presented and 
published data. As PIs, Drs. Bruce and Harari will retain a spot as both first and last author on all manuscripts, unless  either elects to forgo this. Co- Is will have input into all remaining authorship 
spots.  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 84 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 84 20 LITERATURE  REFERENCES 
 
Almstahl, A, Wikstrom, M, and Groenink, J. 2001. Lactoferrin, Amylase and Mucin Muc5b and 
Their Relation to the Oral Microflora in Hyposalivation of Different Origins. Oral Microbiol 
Immunol, 16(6), 345 -352.  
Barratt, G, Saint- Pi[INVESTIGATOR_11958] -Chazalet, M, and Loiseau, PM. 2009. Cellular Transport and Lipid 
Interactions of Miltefosine. Curr Drug Metab, 10 (3), 247 -255.  
Besemer, A, and Bednarz, B. 2014. Su- E-T-345: Validation of a Patient -Specific Monte Carlo 
Targeted Radionuclide Therapy Dosimetry Platform. Medical Physics (41), 303- 304.  
Besemer, AE, Titz, B, Grudzinski, JJ, Weichert, JP, Kuo, JS, Robins, HI, Hall, LT, and Bednarz, 
BP. 2017. Impact of Pet and Mri Threshold- Based Tumor Volume Segmentation on Patient -
Specific Targeted Radionuclide Therapy Dosimetry Using Clr1404. Phys Med Biol, 62(15), 
6008- 6025. doi:10.1088/1361- 6560/aa716d  
Besemer, AE, Yang, YM, Grudzinski, JJ, Hall, LT, and Bednarz, BP. 2018. Development and 
Validation of Rapid: A Patient -Specific Monte Carlo Three- Dimensional Internal Dosimetry 
Platform. Cancer Biother Radiopharm, 33(4), 155- 165. doi:10.1089/cbr.2018.[ADDRESS_445966], M, de Graeff, A, Boysen, M, Evensen, JF, Biorklund, A, 
de Leeuw, JR, Fayers, PM, Jannert, M, Westin, T, and Kaasa, S. 1999. Quality of Life in Head and Neck Cancer Patients: Validation of the European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire- H&N35. J Clin Oncol, 17 (3), 1008-
1019. doi:10.1200/jco.1999.17.3.1008  
Chen, AM, Phillips, TL, and Lee, NY. 2011. Practical Considerations in the Re- Irradiation of 
Recurrent and Second Primary Head- and-Neck Cancer: Who, Why, How, and How Much? 
Int J Radiat Oncol Biol Phys, 81(5), 1211 -1219. doi:10.1016/j.ijrobp.2011.06.[ADDRESS_445967]. 2009. Prevalence of Perceived 
Dysphagia and Quality -of-Life Impairment in a Geriatric Population. Dysphagia, 24(1), 1 -6. 
doi:10.1007/s00455- 008-9156- 1 
Chitra, S, and Shyamala Devi, CS. 2008. Effects of Radiation and Alpha- Tocopherol on Saliva 
Flow Rate, Amylase Activity, Total Protein and Electrolyte Levels in Oral Cavity Cancer. Indian J Dent Res, 19(3), 213- 218.  
Cognetti, DM, Weber, RS, and Lai, SY. 2008. Head and Neck Cancer: An Evolving Treatment 
Paradigm. Cancer, 113([ADDRESS_445968]), 1911- 1932. doi:10.1002/cncr.[ADDRESS_445969] of Conventional Radiotherapy on Health- Related Quality of Life 
and Critical Functions of the Head and Neck. Int J Radiat Oncol Biol Phys, 65(4), 1051 -
1062. doi:10.1016/j.ijrobp.2006.01.054  
Dawes, C. 1987. Physiological Factors Affecting Salivary Flow Rate, Oral Sugar Clearance, and 
the Sensation of Dry Mouth in Man. J Dent Res, 66 Spec No, 648- 653. 
doi:10.1177/00220345870660s107  
Dawson, LA, Myers, LL, Bradford, CR, Chepeha, DB, Hogikyan, ND, Teknos, TN, Terrell, JE, 
Wolf, GT, and Eisbruch, A. 2001. Conformal Re- Irradiation of Recurrent and New Primary 
Head- and-Neck Cancer. Int J Radiat Oncol Biol Phys, 50(2), [ADDRESS_445970]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 85 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 85 De Crevoisier, R, Bourhis, J, Domenge, C, Wibault, P, Koscielny, S, Lusinchi, A, Mamelle, G, 
Janot, F, Julieron, M, Leridant, AM, Marandas, P, Armand, JP, Schwaab, G, Luboinski, B, 
and Eschwege, F. 1998. Full -Dose Reirradiation for Unresectable Head and Neck 
Carcinoma: Experience at the Gustave- Roussy Institute in a Series of 169 Patients. J Clin 
Oncol, 16(11), 3556- 3562. doi:10.1200/jco.1998.16.11.3556  
Deming, DA, Maher, ME, Leystra, AA, Grudzinski, JP, Clipson, L, Albrecht, DM, Washington, MK, 
Matkowskyj, KA, Hall, LT, Lubner, SJ, Weichert, JP, and Halberg, RB. 2014. Phospholipid Ether Analogs for the Detection of Colorectal Tumors. PLoS One, 9 (10), e109668. 
doi:10.1371/journal.pone.[ADDRESS_445971], CH, Roesink, JM, Raaijmakers, CP, van den Keijbus, PA, Brand, HS, and 
Veerman, EC. 2012. Muc5b Levels in Submandibular Gland Saliva of Patients Treated with Radiotherapy for Head -and-Neck Cancer: A Pi[INVESTIGATOR_16116]. Radiat Oncol, 7, 91. 
doi:10.1186/1748- 717x -7-[ADDRESS_445972], R, Dancey, J, Arbuck, 
S, Gwyther, S, Mooney, M, Rubinstein, L, Shankar, L, Dodd, L, Kaplan, R, Lacombe, D, and Verweij, J. 2009. New Response Evaluation Criteria in Solid Tumours: Revised Recist Guideline (Version 1.1). Eur J Cancer, 45(2), 228- 247. doi:10.1016/j.ejca.2008.10.026  
Forastiere, A, Koch, W, Trotti, A, and Sidransky, D. 2001. Head and Neck Cancer. N Engl J Med, 
345(26), 1890- 1900. doi:10.1056/NEJMra001375  
Forastiere, A, Weber, R, and Ang, K. 2008. Treatment of Head and Neck Cancer. N Engl J Med, 
358(10), 1076; author reply 1077- 1078. doi:10.1056/NEJMc073274  
Gandek, B, Ware, JE, Aaronson, NK, Apolone, G, Bjorner, JB, Brazier, JE, Bullinger, M, Kaasa, S, 
Leplege, A, Prieto, L, and Sullivan, M. 1998. Cross -Validation of Item Selection and Scoring 
for the Sf- 12 Health Survey in Nine Countries: Results from the Iqola Project. International 
Quality of Life Assessment. J Clin Epi[INVESTIGATOR_5541], 51 (11), 1171- 1178.  
Gao, X, Lowry, PR, Zhou, X, Depry, C, Wei, Z, Wong, GW, and Zhang, J. 2011. Pi3k/Akt 
Signaling Requires Spatial Compartmentalization in Plasma Membrane Microdomains. Proc Natl Acad Sci U S A, 108(35), [ZIP_CODE] -[ZIP_CODE]. doi:10.1073/pnas.[PHONE_7422]  
Hackshaw, A, Harmer, C, Mallick, U, Haq, M, and Franklyn, JA. 2007. 131i Activity for Remnant 
Ablation in Patients with Differentiated Thyroid Cancer: A Systematic Review. J Clin Endocrinol Metab, 92(1), 28- 38. doi:10.1210/jc.2006- 1345  
Hammerlid, E, Silander, E, Hornestam, L, and Sullivan, M. 2001. Health- Related Quality of Life 
Three Years after Diagnosis of Head and Neck Cancer --a Longitudinal Study. Head Neck, 
23(2), 113 -125.  
Hehr, T, Classen, J, Belka, C, Welz, S, Schafer, J, Koitschev, A, Bamberg, M, and Budach, W. 
2005. Reirradiation Alternating with Docetaxel and Cisplatin in Inoperable Recurrence of Head- and-Neck Cancer: A Prospective Phase I/Ii Trial. Int J Radiat Oncol Biol Phys, 61(5), 
1423- 1431. doi:10.1016/j.ijrobp.2004.08.020  
Henson, BS, Inglehart, MR, Eisbruch, A, and Ship, JA. 2001. Preserved Salivary Output and 
Xerostomia- Related Quality of Life in Head and Neck Cancer Patients Receiving Parotid-
Sparing Radiotherapy. Oral Oncol, 37(1), [ADDRESS_445973]/Retest Study of the European 
Organization for Research and Treatment of Cancer Core Quality -of-Life Questionnaire. J 
Clin Oncol, 13 (5), 1249 -1254. doi:10.1200/jco.1995.13.5.[ADDRESS_445974]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 86 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 86 Hoebers, F, Heemsbergen, W, Moor, S, Lopez, M, Klop, M, Tesselaar, M, and Rasch, C. 2011. 
Reirradiation for Head- and-Neck Cancer: Delicate Balance between Effectiveness and 
Toxicity. Int J Radiat Oncol Biol Phys, 81(3), e111- 118. doi:10.1016/j.ijrobp.2011.01.004  
Hu, YJ, Wang, Q, Jiang, YT, Ma, R, Xia, WW, Tang, ZS, Liu, Z, Liang, JP, and Huang, ZW. 2013. 
Characterization of Oral Bacterial Diversity of Irradiated Patients by [CONTACT_79081]- Throughput 
Sequencing. Int J Oral Sci, 5 (1), 21 -25. doi:10.1038/ijos.2013.15  
Ji, Y, Li, Y, and Nebiyou Bekele, B. 2007. Dose- Finding in Phase I Clinical Trials Based on 
Toxicity Probability Intervals. Clin Trials, 4 (3), 235- 244. doi:10.1177/1740774507079442  
Ji, Y, and Wang, SJ. 2013. Modified Toxicity Probability Interval Design: A Safer and More 
Reliable Method Than the 3 + 3 Design for Practical Phase I Trials. J Clin Oncol, 31 (14), 
1785- 1791. doi:10.1200/jco.2012.45.7903  
Kasperts, N, Slotman, B, Leemans, CR, and Langendijk, JA. 2005. A Review on Re- Irradiation for 
Recurrent and Second Primary Head and Neck Cancer. Oral Oncol, 41(3), 225- 243. 
doi:10.1016/j.oraloncology.2004.07.[ADDRESS_445975], 35(6), 814- 824.  
Kemmler, G, Holzner, B, Kopp, M, Dunser, M, Margreiter, R, Greil, R, and Sperner -Unterweger, B. 
1999. Comparison of Two Quality -of-Life Instruments for Cancer Patients: The Functional 
Assessment of Cancer Therapy -General and the European Organization for R esearch and 
Treatment of Cancer Quality of Life Questionnaire- C30. J Clin Oncol, 17 (9), 2932- 2940. 
doi:10.1200/jco.1999.17.9.2932  
Kramer, NM, Horwitz, EM, Cheng, J, Ridge, JA, Feigenberg, SJ, Cohen, RB, Nicolaou, N, 
Sherman, EJ, Babb, JS, Damsker, JA, and Langer, CJ. 2005. Toxicity and Outcome 
Analysis of Patients with Recurrent Head and Neck Cancer Treated with Hyperfractionated Split-Course Reirradiation and Concurrent Cisplatin and Paclitaxel Chemotherapy from 
Two Prospective Phase I and Ii Studies. Head Neck, 27(5), 406- 414. 
doi:10.1002/hed.[ZIP_CODE]  
Langer, CJ, Harris, J, Horwitz, EM, Nicolaou, N, Kies, M, Curran, W, Wong, S, and Ang, K. 2007. 
Phase Ii Study of Low -Dose Paclitaxel and Cisplatin in Combination with Split -Course 
Concomitant Twice -Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head 
and Neck: Results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol, 25(30), 4800- 4805. doi:10.1200/jco.2006.07.9194  
Li, YC, Park, MJ, Ye, SK, Kim, CW, and Kim, YN. 2006. Elevated Levels of Cholesterol -Rich Lipid 
Rafts in Cancer Cells Are Correlated with Apoptosis Sensitivity Induced by [CONTACT_357380] -
Depleting Agents. Am J Pathol, 168(4), 1107- 1118; quiz 1404- 1105. 
doi:10.2353/ajpath.2006.050959  
Lingwood, D, and Simons, K. 2010. Lipid Rafts as a Membrane- Organizing Principle. Science, 
327(5961), 46- 50. doi:10.1126/science.[ADDRESS_445976], MA, D'Antonio, LL, Cella, DF, Siston, A, Mumby, P, Haraf, D, and Vokes, E. 1996a. The 
Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy -Head and Neck Scale. A Study of Utility and Validity. 
Cancer, 77(11), 2294- 2301. doi:10.1002/(sici)1097- 0142(19960601)77:11<2294::aid-
cncr17>3.0.co;2- s 
Cellectar                                                                                  04Oct  [ADDRESS_445977], MA, Ritter -Sterr, C, and Lansky, SB. 1990. A Performance Status Scale for Head and Neck 
Cancer Patients. Cancer, 66(3), [ADDRESS_445978], MA, Ritter -Sterr, CA, Baker, TM, Colangelo, LA, Matz, G, Pauloski, BR, and Logemann, JA. 
1996b. Longitudinal Assessment of Quality of Life in Laryngeal Cancer Patients. Head 
Neck, 18 (1), 1 -10. doi:10.1002/(sici)1097- 0347(199601/02)18:1<1::aid- hed1>3.0.co;2- 7 
Logemann, JA, Smith, CH, Pauloski, BR, Rademaker, AW, Lazarus, CL, Colangelo, LA, Mittal, B, 
MacCracken, E, Gaziano, J, Stachowiak, L, and Newman, LA. 2001. Effects of Xerostomia on Perception and Performance of Swallow Function. Head Neck, 23(4), 317 -321.  
Macklis, RM, and Pohlman, B. 2006. Radioimmunotherapy for Non- Hodgkin's Lymphoma: A 
Review for Radiation Oncologists. Int J Radiat Oncol Biol Phys, 66(3), 833- 841. 
doi:10.1016/j.ijrobp.2006.05.030  
Mendenhall, WM, Mendenhall, CM, Malyapa, RS, Palta, JR, and Mendenhall, NP. 2008. Re-
Irradiation of Head and Neck Carcinoma. Am J Clin Oncol, 31 (4), 393 -398. 
doi:10.1097/COC.0b013e3181637398  
Mollinedo, F. 2007. Antitumour Ether Lipi[INVESTIGATOR_805]: Proapoptotic Agents with Multiple Therapeutic 
Indications. Expert Opin Ther Patents, 17, 385 -405.  
Mollinedo, F, de la Iglesia- Vicente, J, Gajate, C, Estella -Hermoso de Mendoza, A, Villa- Pulgarin, 
JA, Campanero, MA, and Blanco- Prieto, MJ. 2010. Lipid Raft -Targeted Therapy in Multiple 
Myeloma. Oncogene, 29(26), 3748- 3757. doi:10.1038/onc.2010.131  
Morris, ZS, Weichert, JP, Saker, J, Armstrong, EA, Besemer, A, Bednarz, B, Kimple, RJ, and 
Harari, PM. 2015. Therapeutic Combination of Radiolabeled Clr1404 with External Beam Radiation in Head and Neck Cancer Model Systems. Radiother Oncol, 116(3), 504 -509. 
doi:10.1016/j.radonc.2015.06.015  
Nag, S, Schuller, DE, Martinez -Monge, R, Rodriguez -Villalba, S, Grecula, J, and Bauer, C. 1998. 
Intraoperative Electron Beam Radiotherapy for Previously Irradiated Advanced Head and 
Neck Malignancies. Int J Radiat Oncol Biol Phys, 42(5), 1085- 1089.  
Navazesh, M, and Kumar, SK. 2008. Measuring Salivary Flow: Challenges and Opportunities. J 
Am Dent Assoc, [ADDRESS_445979] , 35s -40s.  
Peters, LJ, O'Sullivan, B, Giralt, J, Fitzgerald, TJ, Trotti, A, Bernier, J, Bourhis, J, Yuen, K, Fisher, 
R, and Rischin, D. 2010. Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results fr om Trog 02.02. J Clin 
Oncol, 28(18), 2996- 3001. doi:10.1200/jco.2009.27.[ADDRESS_445980], E, and Bourhis, J. 2009. Meta -Analysis of Chemotherapy in 
Head and Neck Cancer (Mach- Nc): An Update on 93 Randomised Trials and 17,346 
Patients. Radiother Oncol, 92(1), 4 -14. doi:10.1016/j.radonc.2009.04.[ADDRESS_445981] Century: A Period Analysis. Oncologist, 15(9), 994- 1001. 
doi:10.1634/theoncologist.2009- [ADDRESS_445982] of Parotid Gland- Sparing Intensity -Modulated Radiotherapy on Salivary 
Composition, Flow Rate and Xerostomia Measures. Oral Dis, 23 (7), 990- 1000. 
doi:10.1111/odi.[ZIP_CODE]  
Ringash, J, and Bezjak, A. 2001. A Structured Review of Quality of Life Instruments for Head and 
Neck Cancer Patients. Head Neck, 23(3), [ADDRESS_445983] Protection During Swallowing Using the Penetration- Aspi[INVESTIGATOR_127353]. 
Dysphagia, 14(4), 228 -232. doi:10.1007/pl00009610  
Rogers, SN, Johnson, IA, and Lowe, D. 2010. Xerostomia after Treatment for Oral and 
Oropharyngeal Cancer Using the University of Washington Saliva Domain and a 
Xerostomia- Related Quality -of-Life Scale. Int J Radiat Oncol Biol Phys, 77(1), 16 -23. 
doi:10.1016/j.ijrobp.2009.04.021  
Rogus -Pulia, NM, and Logemann, JA. 2011. Effects of Reduced Saliva Production on Swallowing 
in Patients with Sjogren's Syndrome. Dysphagia, 26 (3), 295 -303. doi:10.1007/s00455- 010-
9311- 3 
Rosenbek, JC, Robbins, JA, Roecker, EB, Coyle, JL, and Wood, JL. 1996. A Penetration-
Aspi[INVESTIGATOR_127353]. Dysphagia, 11(2), 93- 98.  
Rosenthal, DI, Mendoza, TR, Chambers, MS, Asper, JA, Gning, I, Kies, MS, Weber, RS, Lewin, 
JS, Garden, AS, Ang, KK, X, SW, and Cleeland, CS. 2007. Measuring Head and Neck Cancer Symptom Burden: The Development and Validation of the M. D. Anderson Symptom I nventory, Head and Neck Module. Head Neck, 29(10), 923- 931. 
doi:10.1002/hed.[ZIP_CODE]  
Rosenthal, DI, Mendoza, TR, Chambers, MS, Burkett, VS, Garden, AS, Hessell, AC, Lewin, JS, 
Ang, KK, Kies, MS, Gning, I, Wang, XS, and Cleeland, CS. 2008. The M. D. Anderson Symptom Inventory -Head and Neck Module, a Patient -Reported Outcome Instrument, 
Accu rately Predicts the Severity of Radiation- Induced Mucositis. Int J Radiat Oncol Biol 
Phys, 72 (5), 1355 -1361. doi:10.1016/j.ijrobp.2008.02.072  
Salama, JK, Vokes, EE, Chmura, SJ, Milano, MT, Kao, J, Stenson, KM, Witt, ME, and Haraf, DJ. 
2006. Long- Term Outcome of Concurrent Chemotherapy and Reirradiation for Recurrent 
and Second Primary Head- and-Neck Squamous Cell Carcinoma. Int J Radiat Oncol Biol 
Phys, 64 (2), 382 -391. doi:10.1016/j.ijrobp.2005.07.005  
Sherman, AC, Simonton, S, Adams, DC, Vural, E, Owens, B, and Hanna, E. 2000. Assessing 
Quality of Life in Patients with Head and Neck Cancer: Cross -Validation of the European 
Organization for Research and Treatment of Cancer (Eortc) Quality of Life Head and Neck Module (Qlq- H&N35). Arch Otolaryngol Head Neck Surg, 126(4), 459 -467.  
Siegel, RL, Miller, KD, and Jemal, A. 2015. Cancer Statistics, 2015. CA Cancer J Clin, 65 (1), 5 -29. 
doi:10.3322/caac.[ZIP_CODE] 
Siegel, RL, Miller, KD, and Jemal, A. 2018. Cancer Statistics, 2018. CA Cancer J Clin, 68 (1), 7 -30. 
doi:10.3322/caac.[ZIP_CODE] 
Silberstein, EB, Alavi, A, Balon, HR, Clarke, SE, Divgi, C, Gelfand, MJ, Goldsmith, SJ, Jadvar, H, 
Marcus, CS, Martin, WH, Parker, JA, Royal, HD, Sarkar, SD, Stabin, M, and Waxman, AD. 2012. The Snmmi Practice Guideline for Therapy of Thyroid Disease with 131i 3.0. J Nucl Med, 53(10), 1633- 1651. doi:10.2967/jnumed.112.105148  
Sim, C, Soong, YL, Pang, E, Lim, C, Walker, GD, Manton, DJ, Reynolds, EC, and Wee, J. 2018. 
Xerostomia, Salivary Characteristics and Gland Volumes Following Intensity -Modulated 
Radiotherapy for Nasopharyngeal Carcinoma: A Two- Year Follow Up. Aust Dent J, 63 (2), 
217-223. doi:10.1111/adj.[ADDRESS_445984]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 89 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 89 Recurrent Unresectable Head and Neck Cancer. Head Neck, 25(2), 118- 122. 
doi:10.1002/hed.[ZIP_CODE]  
Spencer, SA, Harris, J, Wheeler, RH, Machtay, M, Schultz, C, Spanos, W, Rotman, M, and 
Meredith, R. 2001. Rtog 96- 10: Reirradiation with Concurrent Hydroxyurea and 5-
Fluorouracil in Patients with Squamous Cell Cancer of the Head and Neck. Int J Radiat 
Oncol Biol Phys, 51(5), 1299- 1304.  
Stevens, KR, Jr., Britsch, A, and Moss, WT. 1994. High- Dose Reirradiation of Head and Neck 
Cancer with Curative Intent. Int J Radiat Oncol Biol Phys, 29(4), 687 -698.  
Swanson, KI, Clark, PA, Zhang, RR, Kandela, IK, Farhoud, M, Weichert, JP, and Kuo, JS. 2015. 
Fluorescent Cancer -Selective Alkylphosphocholine Analogs for Intraoperative Glioma 
Detection. Neurosurgery, 76(2), 115 -123; discussion 123- 114. 
doi:10.1227/neu.[ADDRESS_445985], CR, and Wolf, GT. 1997. Head 
and Neck Cancer -Specific Quality of Life: Instrument Validation. Arch Otolaryngol Head 
Neck Surg, 123(10), 1125- 1132.  
Terrell, JE, Ronis, DL, Fowler, KE, Bradford, CR, Chepeha, DB, Prince, ME, Teknos, TN, Wolf, 
GT, and Duffy, SA. 2004. Clinical Predictors of Quality of Life in Patients with Head and Neck Cancer. Arch Otolaryngol Head Neck Surg, 130(4), 401- 408. 
doi:10.1001/archotol.130.4.401  
Tolentino Ede, S, Centurion, BS, Ferreira, LH, Souza, AP, Damante, JH, and Rubira- Bullen, IR. 
2011. Oral Adverse Effects of Head and Neck Radiotherapy: Literature Review and Suggestion of a Clinical Oral Care Guideline for Irradiated Patients. J Appl Oral Sci, 19 (5), 
448-454.  
Valdez, IH, Atkinson, JC, Ship, JA, and Fox, PC. 1993. Major Salivary Gland Function in Patients 
with Radiation -Induced Xerostomia: Flow Rates and Sialochemistry. Int J Radiat Oncol Biol 
Phys, 25 (1), 41 -47.  
van Blitterswijk, WJ, and Verheij, M. 2008. Anticancer Alkylphospholipi[INVESTIGATOR_805]: Mechanisms of Action, 
Cellular Sensitivity and Resistance, and Clinical Prospects. Curr Pharm Des, 14 (21), 2061-
2074.  
Vokes, EE, Weichselbaum, RR, Lippman, SM, and Hong, WK. 1993. Head and Neck Cancer. N 
Engl J Med, 328(3), 184 -194. doi:10.1056/nejm199301213280306  
Ware, J, Kosinski, M, and Keller, S. 1995. Sf -12: How to Score the Sf -[ADDRESS_445986]- Spectrum Cancer Imaging and Therapy. Sci Transl Med, 6(240), 240ra275. 
doi:10.1126/scitranslmed.[ADDRESS_445987]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 90 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 90 APPENDICES  
 
Appendix A : SCHEDULE OF EVENTS  
Appendix B:  ECOG EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE 
STATUS  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 91 of 95 
 _____________________________________________________________________________________________________________________________________________________________  
 
 ___________________________________________________________________________________________________________________________________________ 
 
 
 91 APPENDIX A: SCHEDULE OF EVENTS  
Assessment  Screening Period  Treatment Period  Post Treatment  With-
drawal  
D-[ADDRESS_445988] 
CLR 131 
Infusion  
(± 2 wks)  [ADDRESS_445989] 
EBRT 
(± 4 wks)  [ADDRESS_445990] 
EBRT 
(± 4 wks)  [ADDRESS_445991] 
EBRT 
(± 6 wks)  [ADDRESS_445992] 
EBRT 
(± 6 wks )[ADDRESS_445993] 
CLR 131 
Infusion  
(± 2 wks)  [ADDRESS_445994] 
EBRT 
(± 4 wks)  [ADDRESS_445995] 
EBRT 
(± 4 wks)  [ADDRESS_445996] 
EBRT 
(± 6 wks)  [ADDRESS_445997] 
EBRT 
(± 6 wks )17 With-
drawal
14 
medication (start 
D-1)[ADDRESS_445998]/CT 
Imaging   X7 X8 X         
Disease Assessment  
SOC Diagnostic 
imaging9 X       X  X X  
Treatment  
Administration of CLR 131
10  X15 X15 X15         
SOC EBRT     X        
Notes 
1. Vital signs include blood pressure, pulse, respi[INVESTIGATOR_697], and temperature.  
2. CBC to include red blood cell count, hemoglobin, hematocrit, white blood cell count with differential including % neutrophils, lymphocytes, monocytes, eosinophils and basophils, absolute neutrophil count, and platelet count.  
3. Serum chemistries to include sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, AST, ALT, alkaline phosphatase, total bilirubin, calcium,  protein, 
albumin, and phosphorus . 
Cellectar                                                                                  04Oct  [ADDRESS_445999] 
CLR 131 
Infusion  
(± 2 wks)  [ADDRESS_446000] 
EBRT 
(± 4 wks)  [ADDRESS_446001] 
EBRT 
(± 4 wks)  [ADDRESS_446002] 
EBRT 
(± 6 wks)  [ADDRESS_446003] 
EBRT 
(± 6 wks )[ADDRESS_446004]/CT imaging will be performed approximately approximately [ADDRESS_446005]/CT scan will be performed [ADDRESS_446006] dose. Uptake in the specified site of recurrent/metastatic disease that is to be 
treated with radiation therapy will be determined by [CONTACT_357354].  
8. SPECT/CT imaging will be performed on days 2, 3, 4-6, and 7-[ADDRESS_446007] treatment dose: approximately 14 days, but can be permitted up to 4 weeks. Dosing dates for treatment can be scheduled to start -1 or +3 days to accommodate clinic scheduling (for example: holidays, weekends, treating physician schedules, etc.).  
11. Screening laboratory tests are to be collected within two weeks of dosimetry test dose to determine eligibility   
12. CBC with differential and serum chemistries to be done weekly beginning with D1 treatment dose and continue for 12 weeks. Approximately 6 visits will coincide with CLR 131 administration and/or SOC EBRT visits, and ~6 visits may fall outside of SOC EBRT visits.  
13. Duration of thyroid protection medication: 32-38 days; must take for [ADDRESS_446008]  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 94 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 94 APPENDIX B: ECOG EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE 
STATUS  
 
Grade  Performance Status  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or 
sedentary nature, e.g., light house work, office work  
2 Ambulatory and capable of all self -care but unable to carry out any work activities. Up and 
about more than 50  % of waking hours  
3 Capable of only limited self -care, confined to bed or chair more than 50  % of waking hours  
4 Completely disabled. Cannot carry on any self -care. Totally confined to bed or chair  
5 Dead  
 
As published:  
Oken M M, Creech R H, Tormey D C, et al. Toxicity and response criteria of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol  1982; 5(6):649- 655.  
http://www.ecog -acrin .org [homepage on the Internet] . Eastern Cooperative Oncology Group  and American 
College of Radiology Imaging Network , Robert Comis MD  and Mitchell Schnall, MD PhD , Group Co-Chairs. 
[cited 2016  September  12]. Available from: http://www.ecog- acrin .org/resources/ecog- performance -status  
 
  
Cellectar                                                                                  04Oct  2022  UW19041  
CLR 131 with External Beam Radiation in Head and Neck Cancer  Page 95 of 95 
 ____________________________________________________________________________________________________________________  
 
 _______________________________________________________________________________________________________  
 
 
 95 SUPPLEMENTAL  MATERIALS  
These documents are relevant to the protocol, but they are not considered part of the protocol.  They 
are stored and modified separately. As such, modifications to these documents do not require protocol amendments.  
• Videofluoroscopy  Study Manual  
• CLR 131 Radiopharmaceutical Manual  
• CLR 131 Investigational Brochure  
• CLR 131 Patient Pamphlet  
 
 